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Shelterin is an essential telomeric protein complex that prevents DNA
damage signaling and DNA repair in a compartmentalized manner. We assessed
contributions of the conserved shelterin component, Rap1, to telomere endprotection. Rap1 was first discovered in budding yeast as a transcription factor
and was later shown to bind directly to telomeres. Two important functions of
Rap1 in yeast are: the negative regulation of telomere length, and the inhibition of
the double-strand break (DSB) repair pathway non homologous end-joining
(NHEJ). Mammalian Rap1 interacts with shelterin factor TRF2, to localize to
telomeres, and human Rap1 is implicated in repressing NHEJ.
Surprisingly, removal of Rap1 from telomeres revealed that mouse Rap1
was not required to inhibit NHEJ, but instead was critical for the repression of the
DSB repair pathway homology directed repair (HDR). We showed that complex
formation of Rap1 and TRF2 was most likely necessary to repress HDR,
although the mechanism of how it does so remains to be determined.
Two discrepancies exist between mouse and human Rap1 regarding
repression of NHEJ and regulation of telomere length. Human Rap1 was
proposed to inhibit NHEJ, but we observed no evidence of telomere fusions in

the mouse Rap1 knockout. Similarly, telomere elongation was observed upon
knockdown of human Rap1, but no telomere length phenotypes were observed in
Rap1-deficient mice. With the advent of new genome-editing technologies that
facilitate targeting in human cells, we constructed TALEN-mediated knockouts of
human Rap1 in numerous cell lines. Loss of human Rap1 did not lead to an
induction of NHEJ, or show consistent changes in telomere length, indicating that
similar to mouse Rap1, human Rap1 does not have an important function in
protection or length regulation of human telomeres. Instead, we found that
mammalian Rap1, like its unicellular orthologs, affects gene expression.
Therefore, perhaps the conservation of Rap1 reflects its role in transcriptional
regulation rather than a function at telomeres.
Organismal discrepancies regarding the function of shelterin components,
other than Rap1, also exist. Targeting of human shelterin component POT1
(POT1a/b in the mouse) with shRNAs shows a reduction in 3’ telomere
overhangs and a mild induction of DNA damage signaling. However, deletion of
mouse POT1a and –b results in extended 3’ overhangs and a massive induction
of the DNA damage response. To understand the role of human POT1 in
telomere protection, we used TALENs to generate human knockout cell lines
lacking POT1. We found that similar to mouse POT1, deletion of human POT1
elicited significant DNA damage signaling. Strikingly, the amount of 3’ singlestranded DNA remained unchanged upon loss of POT1, highlighting a potential
difference in overhang regulation between mice and humans.
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Chapter 1: Introduction
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1.1

The structure and function of telomeres
Telomeres are conserved nucleoprotein structures comprised of short

tandem repetitive sequences and highly specific binding proteins that allow linear
DNA to evade recognition as double-stranded breaks (DSBs). Telomeres derive
their name from telos (end) and meros (part) after Hermann Muller irradiated
Drosophila melanogaster and noted that he never found mutants with deletions
or inversions that involved the natural ends of chromosomes 1. Independently,
Barbara McClintock observed from her expansive work in Zea mays that unlike
the natural ends of chromosomes, the ends of broken chromosomes were prone
to cycles of fusion and breakage, which were only halted in zygotes where
broken ends were able to ‘heal’ 2. These early observations illuminated special
features of chromosome termini that preserve genomic integrity.
Telomere repeats vary in sequence and length, with a unifying feature
being the G-rich nature of the strand that runs from 5’ to 3’ to the telomere
terminus. In general the telomere ends in a 3’ single-stranded (ss) overhang.
Budding and fission yeasts have short telomeres of several hundred base pairs 3,
while mammals have much longer telomeres ranging from 10-15 kb in humans
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and from 20-50 kb in mice (Figure 1.1) 5,6.
Mammalian telomeric TTAGGG repeats

7-9

are bound by a six (seven in

mouse) subunit protein complex termed shelterin (reviewed in

10

). Shelterin

consists of two double-strand (ds) DNA binding proteins, TRF1 and TRF2

11-14

.

TRF1 and TRF2 have similar homodimerization (TRFH) domains and both form

2

homodimers that bind two copies of the half site 5’-YTAGGTTR-3’ using their Cterminal Myb/SANT domains

15-17

. The two proteins differ in their N-terminus

where TRF1 has an acidic domain while TRF2 has a basic domain
region comprised minimally of 41 amino acids, present in TRF2

16

. A central

18,19

, but not

TRF1, recruits Rap1 to the telomere 20. Rap1 forms a 1:1 complex with TRF2 21,22
using its C-terminus
the telomere

24

23

, and requires this interaction not only for its localization to

. TRF1 and TRF2 both bind to TIN2

21,25-27

, which serves as a

bridge between the telomeric double-strand and single-strand binding proteins.
TIN2 binds to TPP1
protein POT1

30

26,28,29

, which forms a heterodimer with the ssDNA binding

(POT1a and POT1b in the mouse)

31,32

. POT1 binds to the

telomeric 3’ overhang via its oligonucleotide/oligosaccharide binding (OB)
domains with the minimal binding site 5’-TTAGGGTTAG-3’ 33,34.
The telomeric protein complex of the fission yeast Schizosaccharomyces
pombe (sp) resembles mammalian shelterin in that it contains Taz1
ortholog that binds to duplex DNA and recruits spRap1

36

35

, a TRF

. Bridging proteins Poz1

and Tpz1, proposed to be functional analogs of TIN2 and TPP1, serve to link
Taz1/Rap1 to the ssDNA binding protein POT1

30,37

. The highly diverged

protozoa Trypanosoma brucei (tb) also has a TRF homolog (tbTRF) that binds
telomeres and recruits tbRap1

38,39

. Budding yeast however does not have a

TRF/Taz-like protein at telomeres or a POT1 ortholog. Instead, Rap1 is the de
facto telomere dsDNA binding protein in Saccharomyces cerevisiae (sc)

40-42

.

The single-stranded 3’ overhang in S. cerevisiae is bound by the CST (Cdc13,

3

Stn1, Ten1) complex

43

, which modulates telomere length, recruits telomerase

and protects the telomere terminus

44-47

. S. pombe contains Stn1 and Ten1 that

bind to ssDNA and are required for telomere protection

48

. A similar CST

complex, originally identified as an accessory factor of DNA polymerase αprimase 49,50, also exists in mammalian cells where its subunits are referred to as
CTC1, Stn1 and Ten1. Mammalian CST participates in overhang maintenance
52,53

51

, but its function is different from budding yeast and its recruitment to

telomeres is mediated by TPP1 and POT1

52,54

. Despite the divergent nature of

these complexes, they all perform the same function – the maintenance and
protection of telomeres.

4

Figure 1.1 Telomere binding complexes in mammals and yeast. Telomere sequence repeats
and associated binding complexes are depicted here. Approximate telomere lengths for duplex
DNA and single-stranded overhang are indicated below.
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1.2

Threats to chromosome termini
Chromosome ends face two ominous threats referred to as the end-

replication problem and the end-protection problem. The end-replication problem
originates from the inability of DNA replication to fully synthesize the 3’ ends of
linear DNA, which would result in shorter telomeres with every cell division
thereby limiting the replicative potential of the cell

55-57

. The end-protection

problem refers to the propensity of chromosome ends to be recognized as a
DSB, which would result in disastrous consequences such as cell cycle arrest or
apoptosis if DNA damage signaling and DSB repair were inappropriately
activated (reviewed in 58).

1.2.1 Telomerase counteracts the end-replication problem
Semi-conservative DNA replication involves two modes of DNA synthesis,
leading- and lagging-strand synthesis. In leading-strand synthesis, the
polymerase moves in the same direction as the replication fork allowing the
molecule to be replicated to the very end, presumably resulting in a blunt end. In
lagging-strand synthesis, DNA is synthesized in the opposite direction to the
replication fork, necessitating RNA primers to initiate DNA synthesis in short
stretches known as Okazaki fragments that are eventually ligated together once
the RNA primers have been removed (reviewed in

59

). At a DNA end, lagging-

strand synthesis could be incomplete due to lack of priming for the most distal

6

Okazaki fragment or due to removal of the most distal RNA primer, thus resulting
in loss of the terminal sequence in the daughter cell 60.
In 1961 Leonard Hayflick noted that normal human fibroblasts are able to
divide in culture for a limited number of (between 40-60) population doublings
(PDs), after which they senesce

57

. This proliferative barrier was termed the

Hayflick limit. Further work has illustrated that this phenotype was likely due to
telomere shortening, and in order to bypass replicative senescence, cells with
limiting telomere lengths require a mechanism by which telomere length can be
maintained

61

. While fibroblasts tend to senesce with approximate telomere

lengths of 5-7 kb, it is unclear what the minimal length requirement is for proper
telomere function (reviewed in 62).
One solution to the end-replication problem is provided by telomerase, a
ribonucleoprotein enzyme. The telomerase RNA component, TERC or TR,
serves as a template for synthesis of the G-rich telomeric strand by the catalytic
subunit TERT (telomerase reverse transcriptase). The prediction that a terminal
transferase-like activity extended chromosome ends was based on the ability of
yeast to maintain linearized plasmids containing ciliate telomeres, by addition of
repetitive G-rich sequences
from the ciliate Tetrahymena

63

. The RNA component of telomerase was cloned

64

. Genetic screens in S. cerevisiae for senescence

mutants that displayed progressive telomere shortening

65,66

, alongside

biochemical fractionation of factors that co-purified with telomerase activity in
Euplotes aediculatus

67

led to the discovery of the telomerase catalytic subunit
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Est2 (ever shorter telomeres 2). Following this discovery, mammalian
components of telomerase were rapidly identified

68-70

. Indeed genetically

engineered mice lacking TERC display shortening telomeres over several
generations and exhibit chromosomal abnormalities by the fourth generation 71.
In human cells telomerase is expressed in the germline, but not in most
somatic tissues

72

. However, telomerase activity is readily detectable in

immortalized human cell lines that have either been transformed
from tumors (reviewed in

62

73

or derived

). Approximately 90% of tumour biopsies tested were

shown to express telomerase

74

. Lack of telomerase expression in somatic

tissues suggests that limiting the replicative potential of a cell acts as a barrier to
tumor development, and premalignant or malignant cells must reactivate
telomerase or use an alternative method of telomere length maintenance to
acquire their immortal properties.
Examination of other mammals such as elephants and whales indicated
they have similar telomere lengths to humans and no telomerase activity in
somatic cells. In contrast to these large long-lived mammals, mice and other
short-lived mammals such as shrews and opossums have longer telomeres than
humans and constitutive telomerase activity

6

. Gomes et al. noted that

telomerase activity and telomere length generally correlated inversely with body
size and lifespan, giving rise to the proposal that animals with a short lifespan
accrue a lower mutational load and therefore may not require replicative aging as
a tumor suppressor mechanism. It is clear that while telomerase is necessary to
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counteract the end-replication problem, its expression and activity must be
meticulously controlled.

1.2.2 Telomere length regulation by telomere-binding proteins
Initial insights into the mechanism of telomere length regulation were
derived from studies in S. cerevisiae where increasing the number of scRap1
binding sites resulted in proportional shortening of the telomere

75

. Thus a cis-

acting protein-counting mechanism was proposed where telomere-repeat
addition by telomerase was inhibited based on the number of Rap1 molecules
bound to the telomere. In agreement with these results, overexpression of TRF1
in a subclone of HT1080s (HTC75; a human fibrosarcoma telomerase-positivie
cell line) led to telomere shortening, while expression of a dominant negative
mutant of TRF1 (TRF166-385) that diminished TRF1 at telomeres resulted in
telomere elongation

76

. Overexpression of TRF2 also led to telomere shortening

and telomerase activity was not affected by TRF1 or TRF2

76,77

. Thus the two

dsDNA binding proteins negatively regulate telomere length through a similar
‘protein-counting’ mechanism as shown in yeast 75. Similarly, when double-strand
telomere binding protein Taz1 was deleted in S. pombe, negative regulation of
telomere length was abolished. Interestingly, when spRap1 was deleted,
telomeres also elongated

36

, suggesting that recruitment to telomeres, as

opposed to direct binding to telomeres, might be sufficient for telomere length
control.
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Surprisingly,
lengthening

20

overexpression

of

human

Rap1

leads

to

telomere

, but this elongation is observed even when a Rap1 mutant

defective in localization to the telomere is overexpressed

23

. Considering the

large nucleoplasmic pool of Rap1 that accumulated when exogenously
expressed, it was hypothesized that the non-telomeric Rap1 titrates away a
telomere-associated factor involved in length regulation, that otherwise along with
Rap1 would inhibit telomere elongation. Mild extension of telomeres after partial
knockdown of Rap1 in HTC75 cells provided further support for Rap1 as a
negative regulator of telomere length 78.
Telomeres also elongated when POT1 binding to ssDNA was inhibited by
expression of a POT1 mutant lacking its OB fold, POT1ΔOB
and TPP1 levels reduced by shRNAs
could not bind TPP1

25

80 29

79

. Furthermore, TIN2

and expression of TIN2 mutants that

resulted in telomere elongation, illustrating that

recruitment of POT1 is required for negative regulation of telomere length.
However, TPP1 and POT1 have also been implicated in the positive regulation of
telomerase. The TPP1/POT1 heterodimer was shown to enhance telomerase
processivity in vitro
with POT1/TPP1

82

TERT to telomeres

81

, with telomerase acting preferentially on substrates coated

. In addition, the OB fold of TPP1 can bind to and recruit
81,83-85

. Specifically, a group of surface-exposed amino acids

in the OB fold of TPP1, referred to collectively as the TEL patch, is required for
recruitment and activation of telomerase 86,87.
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1.2.3 The end-protection problem
The integrity of the genome is constantly threatened by internal processes
such as errors introduced during DNA replication and external sources such as
genotoxic agents of radiation. Various mechanisms are in place to detect
damaged DNA, collectively referred to as the DNA damage response (DDR), and
to fix these lesions with DNA repair pathways. Mammalian DDR signaling occurs
primarily through two kinases, the ATM (ataxia telangiectasia mutated) kinase,
activated by the MRN (Mre11-Rad50-Nbs1) complex that senses DSBs, and the
ATR (ATM and Rad3 related) kinase that is activated by the binding of
Replication Protein A (RPA) to ssDNA (reviewed in

88

). Chromosome ends are

vulnerable to both of these pathways with the telomere terminus being
recognized by ATM and the single-stranded overhang being a substrate for ATR
activation.
Activation of ATM and/or ATR triggers cell-cycle checkpoints by
phosphorylation of downstream effectors Chk2
that phosphorylate Cdc25 phosphatases

94

89-91

and Chk1

92,93

respectively,

, which in turn act to reduce the

activity of cyclin-dependent kinases (CDKs), thereby leading to rapid cell-cycle
arrest in intra-S or G2/M

95,96

. Phosphorylation of p53

97-100

and downstream

signaling also occurs to initiate a delayed response to DNA damage, leading to
cell cycle arrest at the G1/S transition and senescence or apoptosis. These
processes are thought to allow time for DNA repair to occur and prevent
transmission of damaged DNA to daughter cells. Coupled with checkpoint

11

activation, signaling by ATM and ATR also promotes a localized response at the
site of the lesion by recruitment and/or activation of DNA repair factors. Both
ATM 101 and ATR 102 phosphorylate histone H2AX (γH2AX) in chromatin proximal
to the damaged lesion. MDC1 (Mediator of DNA damage checkpoint 1) binds to
γH2AX and serves to amplify the DNA damage response

103-105

. Subsequent

recruitment of E3 ubiquitin ligase RNF168 leads to ubiquitylation of lysine 15 on
histone H2A or H2AX

106

resulting in recruitment of the DNA repair effector

53BP1 (tumor suppressor p53 binding protein 1)

107

. These DNA damage

response proteins are not normally detected at the telomere; however, upon
induction of telomere damage, H2AX becomes phosphorylated in the telomeric
chromatin and DNA repair factors such as 53BP1 accumulate at the telomere.
These indices of local DNA damage signaling are frequently used as readouts for
telomere dysfunction 108,109.
DSB repair occurs through two major pathways, non homologous endjoining (NHEJ) and homology-directed repair (HDR). NHEJ is the main method of
repairing breaks in the G1 phase of the cell cycle, while HDR predominates in
S/G2 when the presence of a sister chromatid can provide a template for errorfree repair. Two forms of NHEJ have been described: classical- and alternativeNHEJ (c-NHEJ and alt-NHEJ 110,111). Essential components of c-NHEJ 112 consist
of the Ku70/80 heterodimer which binds to DSBs

113,114

, and DNA Ligase IV

(Lig4) which is responsible for ligating the ends 115. Alt-NHEJ on the other hand is
promoted by PARP1 (poly adenosine diphosphate ribose polymerase 1)

12

116

,

requires resection of the DNA end, and then makes use of small
microhomologies and DNA Ligase 3 (Lig3)

117

to ligate the ends. Ku70/80 has

been shown to inhibit alt-NHEJ, potentially by competing with PARP1 for DSBs
118

. Both types of NHEJ have been shown to be active at dysfunctional telomeres

24,119-121

. Inappropriate repair of chromosome ends by NHEJ results in fused

dicentric chromosomes that are unstable in mitosis and can initiate breakagefusion-bridge (BFB) cycles thereby leading to genomic instability 2.
The central tenets of HDR are resection of a 5’ end to generate a 3’
ssDNA overhang, formation of the Rad51 (radiation sensitive 51) filament to
conduct a homology search, followed by strand invasion into a homologous
region to initiate DNA repair (Figure 1.2). Termination of the telomere in a 3’
single-stranded overhang makes it primed for HDR.
The MRN complex has been implicated in promoting DSB resection in
cooperation with CtIP

122

, as well as BRCA1 (breast cancer 1)

123

. In addition,

Exo1, a 5’ to 3’ exonuclease, in concert with Bloom (BLM), a member of the
RecQ helicase family, have also been shown to mediate resection at DSBs
124,125

. Following resection, the current model derived from studies in yeast is that

RPA initially coats the available ssDNA to facilitate assembly of the presynaptic
filament and remove secondary structures within the ssDNA

126-128

. Mediator

protein BRCA2 (breast cancer 2) subsequently assists in displacement of RPA
and loading of Rad51 to form the pre-synaptic filament

129-131

. Following strand

invasion into the region of homology and DNA synthesis, ‘second end capture’

13

can then occur where the strand not involved in initial invasion is captured to form
a double Holliday junction (dHJ). If this dHJ is dissolved through the helicase
action of BLM in conjunction with the topoisomerase TOP3α

132

, the resulting

product will be a non-crossover and innocuous to the cell (Figure 1.2A).
However, if the dHJ is processed through resolvases such as the heterodimer
Mus81-Eme or GEN1, the resulting outcome can be a crossover

133-135

(Figure

1.2B), which could have deleterious consequences at the telomere.
Due to the repetitive nature of telomeric DNA, strand invasion could take
place at any point along the telomere and if the crossover results in an unequal
exchange, the outcome is one lengthened telomere and one shortened telomere.
This becomes problematic for the daughter cell that inherits the shorter telomere
that can be dysfunctional or limit the replicative potential of the cell. These
crossover events can be detected at dysfunctional telomeres by an assay called
CO-FISH and are called telomeric-sister chromatid exchanges (T-SCEs)

136

(Figure 1.3). Unbridled HDR at the telomere is an alternative method (ALT,
Alternative lengthening of telomeres) for telomere maintenance in the absence of
telomerase (reviewed in 137). ALT has been observed both in in vitro immortalized
human cells and in a subset of human cancers

138,139

, further illustrating the need

for repression of HDR at the telomere. Alternatively, a process termed break
induced replication (BIR) occurs when only one DSB is available for repair, for
which the end of the telomere may be a likely substrate (Figure 1.2D). After
strand invasion DNA synthesis may occur using the migrating D loop as a

14

template

140,141

, recently referred to as bubble migration

142,143

, with fill-in

synthesis replicating the lagging strand. This process could potentially continue
along for the length of the chromatid. In this case, while the danger of unequal TSCEs is not preeminent, BIR could cause excessive lengthening of telomeres
and affect the normal telomere-driven senescence program 144.
Another threat to telomeres includes their susceptibility to undergo
excessive resection of their 5’ end during the process of overhang generation.
While telomeric overhangs naturally occur during lagging strand synthesis,
leading ends would presumably require additional processing for overhang
formation

145

. Telomeres require the 3’ overhang both for protection from DNA

repair and to create a substrate for telomerase, yet this process must be carefully
controlled and inhibit excessive nucelolytic degradation.
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Figure 1.2 Homology-directed repair. Schematic illustrating processing steps in homology
directed repair and potential outcomes. (A) Non-crossover products occur when double Holliday
junctions (dHJ) are dissolved. (B) Both non-crossovers and crossovers can be the result dHJ
resolution by nucleases. Non-crossovers can be detected by the CO-FISH assay (Figure 1.3A).
(C) Break-induced replication is an alternate form of repair that can occur when only one DSB is
available for repair, for example the telomere.
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154

. (A) Chromosome orientation
Figure 1.3 CO-FISH detects T-SCEs. Adapted from
fluorescence in situ hybridization (CO-FISH) is a method that can detect HDR events at the
telomere that have been resolved as crossovers. Briefly, cells are incubated with BrdU and BrdC
for one round of replication. Metaphases are then harvested and treated with UV to generate
nicks in the newly synthesized strand due to BrdU/C sensitivity. This strand is then digested with
Exonuclease III, leaving the parental DNA strands intact. Due to the G-rich and C-rich nature of
complementary strands of telomeric DNA, exchange of sequence between sisters can be
detected by hybridization and colocalization of fluorescent G-rich and C-rich probes. (B)
Schematic showing telomere-sister chromatid exchanges (T-SCEs). An equal exchange would be
innocuous, however an unequal exchange could be deleterious to the daughter cell that inherits
the shortened telomere.
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1.2.4 Shelterin solves the end-protection problem
Genetically engineered conditional mouse knockouts have revealed that
shelterin components are essential (with an exception discussed in chapter 2)
and disable threats to telomere integrity in a compartmentalized manner (Figure
1.4). TRF2 is responsible for inhibiting ATM activation and subsequent repair by
NHEJ

24

. TRF2 is thought to repress ATM activation and NHEJ by facilitating

formation of a t-loop, where the 3’ overhang strand invades into the telomere
duplex, thereby ‘hiding’ the end from the MRN complex and blocking the loading
of Ku70/80
31,148

146,147

. POT1 represses activation of the ATR kinase at telomeres

. Deletion of TIN2 and TPP1 in MEFs phenocopies the POT1a/b double

knockout, thus revealing recruitment of POT1 to the telomere as the primary
function of these two components

83,149-151

. POT1 is proposed to repress ATR

activation by excluding RPA from binding to the single-stranded overhang
148,152,153

. TRF2 and POT1a/b also appear to prevent HDR since they repress the

formation of T-SCEs when Ku70 is also absent

154,155

. However, the mechanism

for shelterin-mediated repression of T-SCEs is unclear.
In contrast to the other shelterin components, TRF1 does not appear to
play a critical role in protecting telomeres from DNA damage signaling and repair.
Deletion of TRF1 resulted in activation of ATR signaling during progression of Sphase and in the appearance of fragile telomeres in metaphase spreads. These
phenotypes were ascribed to the increase in replication fork-stalling when TRF1
was removed from telomeres

156,157

. DNA helicases BLM and RTEL1 also

18

facilitate replication of the telomere, presumably by removing G quartets that may
form due to the G-rich sequence of telomeric DNA 156,158,159.
Removal of the entire shelterin complex from mouse telomeres resulting in
shelterin-free telomeres revealed that chromosome ends are vulnerable to fusion
even when canonical components of the c-NHEJ pathway, Ku80 and Lig4, are
absent

120

alt-NHEJ

. These fusions events are mediated by PARP1 and Lig3 dependent

120,121

. Detection of HDR in shelterin-free Ku80 deficient cells was not

possible due to high levels of telomere fusions, however T-SCEs were observed
in shelterin-free Lig4- and 53BP1- deficient cells. Additionally, when shelterin was
deleted from 53BP1-deficient cells, telomeres underwent extensive nucleolytic
degradation

120

. Thus, HDR, alt-NHEJ and 5’ end resection are threats to

telomeres that are thwarted redundantly by general repressors and multiple
components of shelterin.
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Figure 1.4 Shelterin solves the end-protection problem. Shelterin components are required to
inhibit DNA damage signaling and repair at chromosome ends. Ku70/80 and 53BP1 acts as
general repressors of HDR and resection respectively, but how they perform their dual function in
telomere protection and promoting DNA repair is not yet understood.
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1.2.5 Phenotypes of TRF2 depletion
Deletion of TRF2 from SV40-immortalized mouse embryonic fibroblasts
(MEFs) led to the concomitant depletion of Rap1 protein from the telomere and
the cell

24

. Removal of TRF2 using dominant negative alleles also results in

diminished levels of Rap1

160

. Consequently, analysis of phenotypes associated

with loss of TRF2 could be due to either TRF2, or Rap1, or both. My aims
(discussed in section 1.4) were to understand the contributions to and
mechanisms of telomere protection endowed by Rap1.
Expression of dominant negative alleles of TRF2 in human cells or
deletion of TRF2 in MEFs leads to activation specifically of the ATM kinase

24,148

.

This signaling can be quantified by the appearance and localization of DNA
repair factors and modifications such as 53BP1 and γH2AX, respectively, to
majority of the telomeres, referred to as TIFs (telomere dysfunction-induced foci)
108

. Depletion of TRF2 also results in phosphorylation of Chk2, activation of p53

and apoptosis, consistent with ATM activation

161

. Massive induction of telomere-

telomere fusions was also observed on metaphase spreads from cells lacking
TRF2. These fusions primarily occurred in G1

162

and were mediated by c-NHEJ

as revealed by their dependency on the presence of Ku70 and Lig4

24,154

. The

fusion of dysfunctional telomeres is promoted by 53BP1-mediated mobility of
telomeres 163,164 and inhibition of resection 165. ATM deficiency abolishes both TIF
formation and telomere fusions upon deletion of TRF2, establishing that DNA
damage signaling is required for NHEJ-mediated DNA repair to occur
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148

. In

addition, deletion of TRF2 in the context of Mre11 or Nbs1 deficiency also
diminishes formation of TIFs and fusions indicating that MRN is required for ATM
activation at dysfunctional telomeres, as it is at DSBs

166-168

. TRF2 protects

telomeres from detection by ATM and repair by NHEJ by sequestering the
overhang in a t-loop, visualized by electron microscopy and STORM imaging
147,169

. T-loop formation is thought to conceal the DNA end, thereby preventing

binding of MRN or Ku70/80. In addition, ATM inhibition at linear telomeres not in
the t-loop configuration may be mediated by the so-called iDDR, a 25 amino acid
stretch (aa 407-431) in TRF2 that inhibits the E3 ubiquitin ligase RNF168,
preventing accumulation of 53BP1 at telomeres 170.
Loss of TRF2 in Ku70-deficient MEFs leads to induction of HDR,
visualized by the appearance of T-SCEs

154

, indicating that TRF2 plays a role in

repressing HDR. The Ku70/80 heterodimer, which is known to repress HDR at
DSBs

171

, represses HDR at telomeres independently of shelterin. The

mechanism by which TRF2 represses HDR is not known.
A third function of TRF2 is the inhibition of t-loop cleavage where the tloop is excised as an extrachromosomal circle and loss of telomeric DNA from
chromosome ends is detectable on metaphase spreads and genomic blots

172

.

The ability of TRF2 to prevent t-loop cleavage and its associated stochastic
telomere losses is dependent on its N-terminal basic domain

172

. Biochemical

experiments have shown that the basic domain of TRF2 can bind and stabilize
Holliday Junctions (HJs), which would be expected to form at the base of the t-

22

loop when branch migration takes place

173,174

. Expression of a TRF2 mutant

lacking the basic domain (TRF2ΔB) was able to repress NHEJ but stochastic
events of t-loop cleavage were observed

172

. T-loop cleavage was diminished in

TRF2ΔB-expressing cells when levels of HJ resolvases Mus81 and Gen1 were
reduced by shRNAs

175

, suggesting TRF2 restrains the action of these HDR-

associated nucleases. Expression of TRF2ΔB in TRF2 and Ku70 null cells does
not however induce T-SCEs

154

, revealing that TRF2 represses t-loop cleavage

by HJ resolvases and HDR-mediated formation of T-SCEs through different
mechanisms.

1.2.6 Phenotypes of POT1 depletion
ATR signaling at telomeres is repressed by the ssDNA binding protein
POT1

148

. Depletion of mouse POT1a results in a TIF response

31,32

that is

exacerbated upon co-deletion of POT1b, however POT1b null MEFs alone
exhibit no TIFs

31

. Deletion of POT1b, but not POT1a results in extended single-

stranded overhangs

31

indicating that POT1a and POT1b have evolved to

perform different functions of telomere protection. An RPA exclusion model has
been proposed to explain POT1 inhibition of ATR activation
prevents RPA from binding to the overhang

153

148,152

, where POT1a

. RPA is substantially more

abundant than the TPP1/POT1 heterodimer and binds single-stranded telomeric
DNA with similar affinity, but the tethering of TPP1/POT1 to the rest of shelterin
by TIN2 is proposed to give POT1 the ability to outcompete RPA 149,176.
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The mechanism by which POT1b maintains telomere overhangs of correct
length involves the recruitment of the CST complex to presumably perform fill-in
synthesis of the C-rich strand. Leading- and lagging- strand overhangs are
generated through different mechanisms, where leading-ends require initial
processing by the Apollo/SNM1B nuclease
27,179,180

177,178

that is recruited by TRF2

. POT1b is required to prevent hyper-resection of both leading and

lagging ends by Apollo. Leading and lagging ends are however both extensively
resected by Exo1 during S/G2

181

in the presence of POT1b

52

. POT1b is then

responsible for recruiting the CST complex that restores overhangs to their
normal length 52.
Few chromosomal abnormalities are noted upon loss of POT1a/b, which
include a low level of telomere fusions that occur in G2, and sister telomere
‘associations’, although the molecular basis of this phenotype is unclear
The

sustained

DNA

damage

induced

by

POT1a/b

deletion

31,182

leads

.

to

endoreduplication and eventually growth arrest 31,183. Deletion of both POT1a/b in
Ku70 deficient cells leads to an induction of T-SCEs

155

, indicating that either

POT1a or POT1b is sufficient to inhibit HDR.
Human POT1 has two isoforms, POT1-FL (full-length) and POT1-55,
which lacks the first of the two OB-folds

184

. No function has been reported for

POT1-55. Depletion of human POT1 with shRNAs results in transient DDR
activation
cells

185

184

, a slight reduction in overhang signals and growth arrest in primary

but not transformed cells

184

. Another feature of POT1 depletion from

24

human cells is loss of specificity of the 5’ end. Greater than 80% of normal
telomere ends have been reported to end in ATC-5’ on the C-rich strand, while
there appears to be less selectivity for terminal nucleotides on the G-rich
strand186. Depletion of human POT1 abrogated sequence precision of the 5’ end
184

. It remains to be seen whether the telomere maintenance mechanisms of

human POT1 resemble those of mouse POT1a and PO1b.

1.3

Proposed functions and mechanisms of action for Rap1

1.3.1 Identification of Rap1
Rap1 was first purified and cloned from S. cerevisiae as a transcriptional
regulator

and

thus

named

repressor/activator

binding

protein

1

187

.

Transcriptional regulation by scRap1 arises from its ability to bind directly to
specific DNA sequences located in several promoter regions including ribosomal
genes, as well as at silencer elements. The activation and silencing domains of
scRap1 have been mapped to the C-terminus of Rap1

188

. The silent information

regulators Sir3p and Sir4p bind to this C-terminal region of Rap1 and function in
sub-telomeric silencing of genes adjacent to telomeres

189,190

. Gene disruption of

Rap1 in S. cerevisiae results in lethality, which was proposed to be due to its
function in activation of ribosomal gene loci
that Rap1 binds directly to telomeric DNA

187

40-42

. Further investigation revealed

and the requirement of Rap1 for

viability was attributed to its role in telomere protection 191.

25

Initially identified in a yeast two-hybrid screen with human TRF2,
mammalian Rap1 was found to be a distant ortholog of scRap1

20

. Although the

sequence conservation is extremely low (too low for a simple BLAST search), the
two Rap1 proteins have a similar domain structure featuring a single N-terminal
BRCT domain, a central region with homology to the Myb DNA binding domain,
and a Rap1-specific C-terminal (RCT) protein-interaction domain (Figure 1.5).
However, unlike budding yeast Rap1, which recognizes telomeric DNA directly
through the cooperation of its Myb domain with a second motif that forms a Myblike fold

41,192

, mammalian Rap1 associates with telomeres solely through its

interaction with TRF2

20

. The Myb domain of mammalian Rap1 is not suited for

DNA binding because its surface lacks positive charge and therefore is more
likely to bind to a protein

193

. The targets of the single BRCT domain in the Rap1

proteins are not known. In other proteins, BRCT domains usually occur as
tandem pairs and can function as a phosphopeptide binding module 194.

1.3.2 Rap1 and telomere length regulation
Telomere length regulation by Rap1 in budding yeast is conducted through
its interaction with Rif1 and Rif2 (Rap1 interacting factor 1 and 2), as evidenced
by the elongation of telomeres in their absence

195,196

. A proposed mechanism of

Rif1 and Rif2 action in the negative regulation of telomere length is by interfering
with recruitment of Tel1 (the ATM ortholog). The MRX (Mre11-Rad50-Xrs2)
complex binds to telomeres in S. cerevisiae and recruits Tel1197,198. Tel1 has
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been shown to preferentially associate with short telomeres

199-201

and facilitate

their elongation. Rap1 binding partners Rif1 and Rif2 are proposed to compete
with Tel1 binding to the MRX complex, hence preventing the subsequent steps
that allow for telomerase recruitment

202

. Additionally, while S. pombe Rif1 does

not bind directly to Rap1, it localizes to the telomere and is involved in regulating
telomere length

36

. Although a mammalian ortholog of Rif1 (not Rif2) has been

identified, it does not localize to functional telomeres, nor is it involved in
telomere length homeostasis

203

. Instead Rif1 localizes to DSBs and

dysfunctional telomeres and promotes NHEJ by inhibiting resection downstream
of 53BP1

165,204-207

. Additionally Rif1 also participates in the intra-S phase

checkpoint, responding to replication stress
firing

209,210

203,208

, and timing of replication origin

. Thus it seems unlikely that hRap1 follows the budding yeast Rap1

paradigm in using Rif1 to maintain telomere length homeostasis.

1.3.3 Rap1 and end-protection
In both S. cerevisiae and S. pombe, Rap1 is required for the prevention of
NHEJ at chromosome ends

191,211

. Some mechanistic insight has been obtained

from studies in S. cerevisiae that indicate Rap1 can protect telomeres from fusion
via its C-terminal interactors Rif2 and Sir4, and also by its central domain (which
includes the DNA binding domain)

212

. Despite not binding to telomeric DNA,

Rap1 in S. pombe has also been shown to inhibit telomere fusions

211

. While

mammalian orthologs of Sir4 and Rif2 do not exist, deletion of TRF2 and Rap1

27

from MEFs resulted in telomere fusions, suggesting mammalian Rap1 may have
retained its function in repressing NHEJ

24

. Furthermore, human Rap1 can block

NHEJ when it binds to TRF2 loaded on a telomeric end-joining substrate in vitro
213

, and a Rap1-fusion protein can reduce telomere fusions when it is tethered to

telomeres that are depleted of TRF2 160.
In several species of budding yeast, namely Kluyveromyces lactis (kl) and
Candida albicans (ca), Rap1 functions in repressing homologous recombination
at the telomere. The K. lactis strain ter1-16T expresses a re-programmed
telomerase that synthesizes telomeres lacking Rap1 binding sites, leading to
elongated telomeres with an especially long 3’ overhang. Electron microscopy of
these cells revealed the formation of T-loop structures and an abundance of tcircles. When Rad52, a bona fide HDR component in budding yeast was absent,
the incidence of t-circles decreased indicating that the t-circles were products of
HDR, suggesting Rap1 binding to telomeres is required to inhibit recombination
214

. Complete deletion of caRap1 also exhibited an abundance of t-circles in

comparison to wild type

215

. Depletion of TRF2 and Rap1 from Ku70 null cells

resulted in T-SCEs, raising the possibility that mammalian Rap1 may also be
required to repress HDR at the telomere 154.
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227

Figure 1.5 Mammalian Rap1 resembles yeast and trypanosome Rap1. Adapted from
.
Schematic representation of conserved protein motifs of Rap1 and its TRF2-like partners in the
indicated organisms. Amino acid positions indicated in schematic of mammalian Rap1
correspond to mouse Rap1. MYB indicates regions with a MYB sequence. MYB-fold indicates a
motif that lacks sequence similarity to the MYB sequence but has a similar fold. MYB-like
indicates sequence similarlity to the MYB-fold of S. cerevisiae, but their structure has not been
determined. S. cerevisiae interacts with several factors important for its functions via its RCT
domain. “RCT” of S. pombe indicates the region of Rap1 that is required for interaction with Taz1.
It is not known whether T. brucei has a RCT domain, but the C-terminus of tbRap1 is not required
for interaction with its TRF interacting partner.
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1.3.4 A role for Rap1 in meiosis and chromatin organization
Telomeres are involved in chromatin reorganization during meiosis in
yeasts, worms and mammals. During meiotic prophase I, telomeres attach to the
nuclear envelope mediated by SUN/KASH-domain nuclear transmembrane
complexes and other meiosis-specific protein complexes (reviewed in

216

).

Following leptotene, telomeres cluster around the centrosome resulting in
bouquet formation, proposed to stimulate homologous chromosome pairing and
meiotic recombination. Rap1 in fission yeast is necessary for telomere clustering
at the spindle pole body during the premeiotic horsetail stage, which in mammals
is analogous to bouquet formation in meiosis 36,217,218. During normal cell division,
telomeres are tethered to the nuclear envelope during the process of nuclear
assembly, potentially mediated by an interaction between Rap1 and SUN1 219.

1.3.5 Non-telomeric functions of mammalian Rap1
Transcriptional regulation by Rap1 has been demonstrated in budding
yeast as well in trypanosomes. Similar to budding yeast tbRap1 largely localizes
to the telomere, but not exclusively. T. brucei normally express one variant
surface glycoprotein (VSG) from subtelomeric loci in a monoallelic fashion.
Knockdown of tbRap1 led to derepression of VSG expression sites causing
simultaneous expression of multiple different VSGs 39.
Unlike in S. cerevisiae, where Rap1 interacts with sirtuins (Sir3p and
Sir4p) that regulate transcription, mammalian Rap1 does not interact with the
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sirtuins, however it has been shown to localize to over 30,000 chromosomeinternal sites and control gene expression, affecting metabolism and body weight
control

220-223

. ChIP-seq for Rap1 in MEFs indicated that it predominantly

localized to chromosome internal loci with [TTAGGG]2 as a consensus motif,
suggesting TRF2-mediated recruitment to these sites. Rap1 was also detected at
telomere sequences containing a mismatch that disrupts TRF2 binding,
suggesting additional interacting partners and modes of recruitment for Rap1

220

.

Indeed, regulation of metabolic genes by Rap1 was independent of its ability to
bind TRF2

221

. Human Rap1 has also been reported to associate with

chromosome internal loci, but the number of sites (~100) is much lower 223.
Another unanticipated function of Rap1 is its role in the modulation of
NFκβ signaling. Rap1 was identified in a gain-of-function screen for regulators of
NFκβ

224

. Despite the predominantly telomeric localization of Rap1, the authors

observed a cytoplasmic fraction of Rap1 that is constitutively associated with Iκβ
kinases (IKKs). IKKs are responsible for phosphorylation and subsequent
degradation of inhibitors of NFκβ (Iκβ proteins). They found that Rap1 requires
interaction with IKKs to activate NFκβ gene expression and suggested that Rap1
directs IKK activity specifically to p65, an inhibitory subunit of NFκβ. These
results are surprising when taking into account data that shows that very little
Rap1 is not bound to TRF2

19

, however it is possible that Rap1 has other

interacting factors that recruit it to the cytoplasm, or Rap1 shuttles back and forth
from the nucleus to the cytoplasm. Numerous Rap1-interacting factors have been
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identified by mass spectrometry and proximity-based YFP fluorescence
complementation screens, yet none of these interactions have been carefully
characterized and it is unclear what roles they may play in protection and
maintenance of telomeres 78,225,226.

1.4

Objectives
The first objective of this thesis was to understand the role of Rap1 in

telomere end-protection. This was carried out using two independent methods:
generation of a Rap1 conditional mouse knockout and analysis of a TRF2 mutant
defective in Rap1 binding. These two approaches revealed that mouse Rap1 was
required to inhibit HDR, but not NHEJ at the telomere.
The second objective, stemming from the discovery that Rap1 represses
telomeric HDR, was to investigate the mechanism of this inhibition. Examination
of a panel of Rap1 mutants indicated that the C-terminus of Rap1 was required to
inhibit HDR. Further analysis suggested that Rap1 needs to be bound to TRF2 in
order to repress HDR, although the mechanism by which Rap1/TRF2 act remains
to be elucidated.
The third objective, facilitated by the development of efficient genomeediting technologies in human cells, was to query the discrepancy between the
claimed functions of mouse and human Rap1. In contrast to mouse Rap1, in vitro
and in vivo data had implicated human Rap1 in shielding telomeres from NHEJ.
In addition, no deregulation of telomere length was noted in mouse cells lacking
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Rap1, whereas human Rap1 had been implicated in telomere length
homeostasis. To determine whether human Rap1 protects telomeres from NHEJ
and negatively regulates telomere length, Rap1 knockouts were generated in a
panel of human cell lines.
The fourth and final objective of this thesis was to construct human
knockouts of POT1 to investigate its functions in and mechanisms of telomere
protection, and to compare the role of human POT1 to those of mouse POT1a
and POT1b.
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Chapter 2: Loss of Rap1 Induces Telomere Recombination
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2.1

Introduction
Previous loss-of-function studies that removed TRF2 from the telomere

also noted concomitant loss of Rap1

24,160

. Rap1 may therefore play a role in

functions ascribed to TRF2, namely repression of the ATM kinase and inhibition
of the DSB repair pathways, NHEJ and HDR

24,148,154,161

. In addition,

overexpression and partial knockdown experiments revealed Rap1 as a potential
regulator of telomere length

23,78

. In order to understand the contribution(s) of

mammalian Rap1 to telomere protection two strategies were devised to remove
Rap1 from the telomere and study the phenotypes of its loss. The two
approaches taken were to 1) make a conditional mouse knockout of Rap1 and 2)
to capitalize on the dependency of Rap1 on its telomeric recruitment by TRF2, by
generating a TRF2-separation-of-function mutant that could fulfill all functions of
TRF2 except interacting with Rap1. The results of these studies are reported
here.

2.2

Results

2.2.1 Deletion of Rap1 does not affect cell and organismal viability
The gene for the mouse Rap1 protein is annotated as TERF2IP (telomeric
repeat binding factor 2 interacting protein) but referred to as Rap1 henceforth.
Because the first exon of Rap1 immediately abuts the essential KARS lysyltRNA-synthetase gene, a conditional knockout strategy was developed where a
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Rap1 floxed (Rap1F) allele was created by flanking exon 2 with LoxP sites (Agnel
Sfeir, Figure 2.1A-C). Deletion of exon 2 by retroviral expression of Cre
recombinase results in a premature stop codon in exon 3. The C-terminus of
Rap1 is encoded by exon 3 and is required for its interaction with TRF2 and
recruitment to the telomere. The resulting Rap1Δex2 allele can potentially encode
a fragment containing the N-terminus of Rap1 (Agnel Sfeir, Figure 2.1A).
Exogenous expression of FLAG-tagged Rap1-ex1 (exon1) showed that this
truncated form of Rap1, if it were produced, would not bind or localize to
telomeres (Agnel Sfeir, Figure 2.1D-F). Indirect immunofluorescence (IF) on
samples where nucleoplasmic proteins had been removed by treatment with
Triton-X showed no visible signal of FLAG Rap1-ex1 (Agnel Sfeir, Figure 2.1E).
Similarly, fractionation of cells expressing FLAG Rap1-ex1 showed that the
protein was largely cytoplasmic and could not be detected in the chromatin
bound fraction (Agnel Sfeir, Figure 2.1F).
Rap1F/F MEFs were isolated at embryonic day 13.5 and immortalized with
SV40 large T antigen (SV40LT). IF and immunoblotting showed that Cre-treated
SV40LT-immortalized Rap1F/F MEFs indeed lacked any detectable full-length or
truncated

Rap1

protein

(Agnel

Sfeir,

Figure

2.2A-C)

and

chromatin

immunoprecipitation (ChIP) showed the loss of Rap1 from telomeres. The
expression and localization of other shelterin components were not significantly
affected (Agnel Sfeir, Figure 2.2D).
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Figure 2.1 Strategy to conditionally delete mouse Rap1. (A) Schematic of Rap1, the mouse
Rap1 (TERF2IP) locus, the targeting construct, the floxed allele, and the Δex2 allele. N, NdeI; B,
BamHI; F1, F2, and R, PCR primers. Rap1 shRNAs shown at the bottom. At right, Rap1Δex2encoded protein. (B) Genomic blot of NdeI-digested DNA from ES cells. Probe in (A). (C)
Genotyping of tail DNAs. Primers in (A). (D) Immunoblot for Rap1 in cells expressing FLAG FLRap1, FLAG Rap1-ex1, or vector control. The schematic below depicts full-length Rap1 protein
(FLAG FL-Rap1) and the protein fragment encoded by exon 1 (FLAG Rap1-ex1). The antigenic
region recognized by Rap1 Ab 1252 is indicated. (E) IF to monitor the localization of FLAG Rap1Δex2/Δex2
MEFs expressing FLAG Rap1-ex1 or FLAG FL-Rap1 are
ex1 and FLAG FL-Rap1. Rap1
Δex2/Δex2
MEFs expressing FLAG Rap1-ex1,
stained with FLAG (green) and TRF1 (red). (F) Rap1
FLAG FL-Rap1 or vector control were fractionated as described in the materials and methods
section and equal fractions of cytoplasmic proteins (CP), nucleoplasmic proteins (NP), and
chromatin-bound proteins (CB) were analyzed by immunobloting with Rap1 Ab 1252.
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Figure 2.2 Deletion of Rap1 does not affect localization of other shelterin components to
telomeres. (A) Loss of Rap1 IF signal from Cre-treated (day 5) Rap1F/F MEFs. Red, Rap1;
green, telomeric FISH; blue, DNA (DAPI). (B) Western blot showing the disappearance of fulllength Rap1 in cells deleted for exon 2. No new Rap1 protein was detected in cells bearing the
Rap1Δex2 allele. (C) Immunoblots for Rap1 (Ab1252), TRF2 (Ab1254), and TRF1 (Ab1449) from
F/F
F/+
Rap1 and Rap1 MEFs five days after Hit&Run-Cre (first lane) or pWZL-Cre (second lane).
F/F
(D) Telomeric ChIPs on Cre-treated (day 5) Rap1 MEFs. Numbers represent ratios of %
telomeric DNA in the ChIPs (pre-immune (PI) signal subtracted) on cells + and -Cre.
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The growth rate of the SV40LT immortalized Rap1Δex2/Δex2 MEFs was
similar to control cells, and primary MEFs lacking wild type Rap1 did not show a
growth arrest or p53 activation

(Agnel Sfeir, Figure 2.3A-C). Furthermore,

Rap1Δex2/Δex2 mice were born at the expected frequencies and were fertile (Agnel
Sfeir, Figure 2.3D). The survival of Rap1Δex2/Δex2 cells and mice argues that Rap1
deletion does not result in major telomere dysfunction, which is known to be
lethal. While there was no evidence of translation of the truncated N-terminus of
Rap1, to conclusively determine that no telomere-protection was being afforded
by this fragment, Rap1Δex2/Δex2 MEFs were infected with an shRNA targeting exon
1 (Agnel Sfeir, Figure 2.3E). Treatment with the shRNA targeting exon 1 did not
induce a growth arrest or other phenotypes typical of telomere dysfunction further
validating the previous conclusions.
In the second approach to remove Rap1 from telomeres, previously
characterized TRF2F/-p53-/- MEFs were used

24

to replace the endogenous TRF2

with a mutant that does not bind to Rap1. A short predicted helix at position 290
in the previously mapped Rap1 binding region (aa 260-360;

20

) was conserved in

TRF2 orthologs but not in TRF1 (Figure 2.4A-B). Two mutations in this region
(A289S and F290S) reduced the interaction between Rap1 and TRF2 in co-IP
experiments (Giulia Celli, Figure 2.4C). To generate TRF2ΔRap1, aa 284-297 were
deleted (Megan van Overbeek, Figure 2.4D). TRF2ΔRap1 failed to bind to Rap1 in
co-IP experiments whereas it retained its previously reported interaction with
Apollo (Megan van Overbeek, Figure 2.4E). TRF2ΔRap1 was expressed in TRF2F/-
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p53-/- MEFs and the endogenous TRF2 was removed with Cre, resulting in
depleted Rap1 protein levels (Megan van Overbeek, Figure 2.4F). Although
TRF2ΔRap1 localized to telomeres efficiently, IF and ChIP indicated that the
telomeres lacked Rap1 (Figure 2.5A-B). Other shelterin components were
affected to an extent (<2-fold; Figure 2.5B) that is not expected to be functionally
significant as heterozygous MEFs and mice lacking one copy of TRF1, TPP1,
TRF2, or POT1a/b display no telomere defect. Assessment of shelterin
occupancy at telomeres by ChIP displayed some variability due to antibody
quality and inexact experimental processing (Figure 2.5B). Despite this variability,
on average less than 10% of residual Rap1 remained at telomeres in TRF2 null
MEFs complemented with TRF2ΔRap1, while levels of other shelterin components
in these cells were approximately 85% or higher, compared to cells
complemented with wild type TRF2 (Figure 2.5B). Consistent with the viability of
Rap1Δex2/Δex2 cells, cells expressing TRF2ΔRap1 proliferated at the same rate as
cells expressing wild type TRF2 (Megan van Overbeek, Figure 2.5C-D).

2.2.2 No induction of DDR or NHEJ at telomeres lacking Rap1
Rap1Δex2/Δex2 cells did not show TIFs and phosphorylation of Chk1 and
Chk2 (Chk1-P, Chk2-P) was not evident (Figure 2.6A-C). Further depletion of
Rap1 mRNA with an shRNA also failed to elicit a DNA damage signal in
Rap1Δex2/Δex2 cells (Figure 2.6B). Consistent with these results, TRF2ΔRap1 was
equivalent to wild type TRF2 in its ability to repress TIFs in cells lacking

40

endogenous TRF2 (Figure 2.6D-F). The mutant form of TRF2 also repressed the
induction of Chk2-P to the same extent as wild type TRF2 (Figure 2.6E). The low
level of Chk2-P observed in Cre-treated TRF2- and TRF2ΔRap1- expressing cells
is likely due to Cre-induced DNA damage, since the phosphorylation of Chk2 was
diminished when using a version of Cre (Hit&Run) that eventually disappears
from the cells due to self-deletion (Figure 2.6F).
Telomere fusions were not induced by deletion of Rap1 and TRF2ΔRap1
had the same ability as wild type TRF2 to repress NHEJ at telomeres (Figure
2.7A-C). However, as previously discussed, NHEJ of telomeres lacking TRF2
requires active DNA damage signaling

148

thus the lack of telomere fusions could

be due to the lack of ATM/ATR activation. In order to initiate DNA damage
signaling specifically at the telomere, we used a TPP1 shRNA to activate the
ATR kinase. This approach previously resulted in the reactivation of NHEJ at
telomeres of TRF2- and ATM-deficient cells

148

. Despite ATR kinase signaling at

telomeres and induction of TIFs elicited by the TPP1 shRNA (Figure 2.6B,D),
Rap1 removal from telomeres did not induce their fusion (Figure 2.7B-C). Thus,
Rap1 does not appear to be required in either the repression of NHEJ or ATM
kinase signaling, explaining why the deletion of Rap1 does not curb cellular or
organismal viability.
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Figure 2.3 Rap1 deletion does not affect cell and organismal viability. (A) Proliferation of
F/F
F/+
and Rap1
MEFs infected as indicated. (B) FACS profiles of
SV40LT-immortalized Rap1
F/F
primary Rap1 cells infected with pWZL-Cre (left panel) or vector control (right panel), analyzed
at day 5 after infection. The percentage of G1, S and G2 cells is noted within the FACS profile.
(C) Immunoblot for Rap1 on MEFs with the indicated genotype, 96 hours after Cre treatment. (D)
∆ex2/+
∆ex2/∆ex2
and Rap1
intercrosses. (E) Western blot showing the effect of
Offspring from Rap1
Rap1 shRNAs 1 and 2 on Rap1 levels in wild type MEFs.
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Figure 2.4 A TRF2 mutant deficient for Rap1 binding. (A) Schematic of TRF2 showing
conservation of a subset of amino acids within the previously mapped Rap1 interaction domain.
(B) Identification of a helical region within the conserved segment. Predicted protein structure
from PredictProtein.org. (C) Co-IPs of FLAG-tagged Rap1 with wild type TRF2, TRF2 mutants or
∆Rap1
mutant. H, predicted helix. (E) Co-IP of Myc-TRF2 or Mycno protein. (D) The TRF2
∆Rap1
with FLAG-Rap1 or FLAG-Apollo from co-transfected 293T cells. In, 2.5% of input. (E)
TRF2
F/-/Immunoblots for TRF2 and Rap1 from TRF2 p53 MEFs expressing the indicated alleles at 72
and 96 hours after Hit&Run-Cre.
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ΔRap1

expression results in diminished levels of Rap1. (A) IF-FISH to monitor
Figure 2.5 TRF2
F/-/∆Rap1
or vector control
TRF2, Rap1, and TIN2 at telomeres in TRF2 p53 MEFs expressing TRF2
F/-/∆Rap1
at
at day 4 after Cre. (B) Telomeric ChIP of TRF2 p53 MEFs expressing TRF2 or TRF2
day 4 post Cre. Duplicate dot blots were probed for telomeric DNA or the dispersed BamHI
∆Rap1
vs. TRF2 expressing
repeats. ChIP ratios represent the % telomeric DNA recovered in TRF2
cells. ChIP ratios are shown from two independent experiments and averages with SEMs are
∆Rap1
in
listed to the right. (C) Immunoblots showing the expression of Rap1, TRF2, and TRF2
F/-/TRF2 p53 MEFs treated with pWZL-Cre for the indicated time-periods. (D) Growth curve of
cells shown in (C) and the vector controls.
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Figure 2.6 No DNA damage signaling at telomeres lacking Rap1. (A) TIF assay on Rap1F/F
MEFs treated with Cre and the indicated shRNA. Red, IF for 53BP1; green, telomeric FISH; blue,
DNA (DAPI). (B) TIF assay quantification. Averages of two independent experiments (n≥100
nuclei each) and SEMs. (C) Chk2-P in Rap1-deficient MEFs. TRF2 null cells and IR-treated cells
(1 hr post 2 Gy,) serve as positive controls. (D) Quantification of TIF assays on TRF2F/-p53-/cells expressing TRF2, TRF2∆Rap1 or vector control at day 4 post Cre. Mean of three
independent experiments (n≥100 nuclei each) and SDs. (E) Chk1 and Chk2 phosphorylation in
TRF2F/-p53-/- MEFs expressing TRF2, TRF2∆Rap1 or vector control. UV (1 hr post 25 J/m2)
and IR (1 hr post 2 Gy) treated cells serve as positive controls. (F) Rap1 and Chk2 immunoblots
of TRF2F/-p53-/- MEFs expressing TRF2, TRF2∆Rap1 or vector control, at 144 hours after
treatment with Hit&Run-Cre.
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F/F

Figure 2.7 Loss of Rap1 does not induce NHEJ. (A) Metaphase chromosomes from Rap1
cells 5 days post Cre. Red, false colored DNA DAPI stain; green, telomeric FISH. (B)
F/F
Quantification of telomere fusions, detected as in (A) in Rap1 MEFs with the indicated Cre and
shRNA treatments. Average % of telomeres fused is given. (C) Quantification of telomere fusions
F/-/∆Rap1
or vector control
in TRF2 p53 MEFs (+ or – Cre, day 4) complemented with TRF2 or TRF2
and treated with TPP1 shRNA as indicated.
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2.2.3 Telomere length and chromatin unchanged in Rap1-deficient cells
To assess the role of Rap1 in telomere length regulation, telomere length
was examined over three generations of mouse breeding and over approximately
50 population doublings in cultured cells lacking Rap1 (Figure 2.8A-C). No overt
changes in telomere length were detected. Furthermore, the amount of the
single-stranded overhang remained unchanged in Rap1-deficient cells (Figure
2.8D).
Mammalian telomeres contain nucleosomes and epigenetic marks that are
characteristic of heterochromatin, such as heavily methylated histones (reviewed
in

228

). Rap1 was not required for the maintenance of telomeric nucleosomal

organization or the methylation of telomeric H3K9 (Agnel Sfeir, Figure 2.9A-C). In
addition, the level of telomeric lncRNA called TERRA (telomeric repeatcontaining RNA; reviewed in

229

) was not affected upon deletion of Rap1 (Agnel

Sfeir, Figure 2.9D).

2.2.4 Rap1 is a repressor of telomere recombination
Homology-directed repair threatens telomere integrity because unequal
telomere-sister chromatid exchanges can change telomere lengths. T-SCEs are
most frequent when either TRF2 or POT1a/b are deleted from Ku-deficient cells
154,155

, although low levels of T-SCEs have been reported for POT1a deficiency

alone 32. To determine whether Rap1 was required for TRF2-mediated repression
of T-SCEs, TRF2ΔRap1 was introduced into SV40LT-immortalized TRF2F/-Ku70-/-
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MEFs, which display frequent T-SCEs upon deletion of TRF2 with Cre. Whereas
the telomeric exchanges were repressed by wild type TRF2, TRF2ΔRap1 failed to
block the telomeric HDR (Fig. 2.10A-C). The frequency of T-SCEs was the same
whether the cells expressed TRF2ΔRap1 or no TRF2 (Figure 2.10D). Furthermore,
T-SCEs were induced by Cre-mediated deletion of Rap1 from Rap1F/FKu70-/cells (Figure 2.10E).
Notably, the T-SCEs occurred despite absence of TIFs in cells lacking
both Ku70 and telomeric Rap1 (Figure 2.11A-B). Basal levels of Chk2-P were
observed in cells lacking Rap1 and Ku70, but these were likely attributable to the
Cre effect and Ku70 deficiency, as they were much lower than the induction of
Chk2-P observed in the absence of TRF2 and Ku70 (Figure 2.11C-D). There
appeared to be no effect on the terminal structure of telomeres in cells lacking
Rap1 and Ku70 (Figure 2.11E).
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Figure 2.8 Rap1 does not affect telomere length maintenance. (A) Telomeric restriction
Δex2/+
mouse and three successive
fragment analysis on cells isolated from the liver of a Rap1
Δex2/Δex2
mice. Telomeric DNA was detected by in-gel hybridization assays
generations of Rap1
using a (CCCAAT)4 probe under denaturing conditions. (B) Telomere length analysis on
Δex2/Δex2
MEFs and wild type cells at the indicated population doublings. (C) Telomere length
Rap1
F/-/ΔRap1
, or vector, plus or minus treatment
analysis of TRF2 p53 cells expressing TRF2, TRF2
with Cre. (D) Loss of Rap1 does not alter the telomeric single-stranded DNA. MEFs with the
indicated genotypes were analyzed at day 5 post Cre treatment using in-gel hybridization to MboI
digested DNA. The panel on the left shows the hybridization signal using a (CCCAAT)4 probe
under native conditions. The panel on the right represents total telomere signal after in situ
denaturation of DNA and re-hybridization with the same probe. The numbers on the bottom
represent the relative overhang signal normalized to the total telomeric repeat signal. Values of
the normalized signal are compared between – Cre (set at 1) and +Cre samples.

	
  

49

Figure 2.9 Telomeric chromatin and transcription unchanged upon Rap1 loss.
(A) Unaltered nucleosomal organization of telomeric chromatin upon loss Rap1. DNA from
F/F
MNase digested nuclei of Rap1 MEFs (+ or – Cre treatment) fractionated on a 1% agarose gel
and stained with ethidium bromide (upper panel) to monitor organization of bulk nucleosomes or
32
blotted and hybridized with a P-(CCCTAA)4 probe (lower panel). The two DNA samples marked
by (*) were switched. The concentration of MNase ranged from 5 – 600 U/ml. (B) Rap1 loss has
F/F
no effect on the heterochromatic marks at telomeres. Telomeric ChIP analysis of Rap1 cells
treated with pWZL Cre or Hit&Run Cre as indicated. Antibodies used are indicated on top. Preimmune serum (PI) is used as a negative control. (C) Quantification of percentages of total
telomeric DNA recovered in the ChIP shown in (B). (D) TERRA levels as detected by Northern
blot analysis on Rap1 MEFs with the indicated genotype and Cre treatment. Ethidium bromide
staining pattern serves as a loading control.
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Figure 2.10 Rap1 is a repressor of telomere recombination. (A) Rap1 and TRF2 from
F/-/∆Rap1
, or vector control analyzed 4 days after Cre.
TRF2 Ku70 MEFs expressing TRF2, TRF2
(B) CO-FISH analysis on cells in (A). Arrows: T-SCEs. (C) Enlarged T-SCE events in Cre-treated
F/-/∆Rap1
. (D) Quantification of T-SCEs as assessed in (B).
TRF2 Ku70 MEFs expressing TRF2
Bars represent averages from three independent experiments (n>1100 chromosome ends each)
and SDs. P values based on Student’s two-tailed t-test. (E) Quantification of T-SCEs as assessed
in (B) in cells of the indicated Rap1 and Ku70 status. Method as in (D). Errors bars: SEMs except
F/F
-/for SDs for Rap1 Ku70 .

51

Figure 2.11 T-SCEs observed in Rap1-deficient cells despite no DNA damage signaling.
F/-/∆Rap1
or
(A) TIF assay on TRF2 Ku70 SV40LT-immortalized MEFs expressing TRF2, TRF2
vector control, before or after treatment with Cre. Red, IF for 53BP1; green, telomeric FISH; blue,
DNA (DAPI). (B) Quantification of TIF assay in (A). (C) Immunoblots for indicated shelterin
components, Chk1 and Chk2 of same cells as in (A). IR (1hr post 2Gy) and UV (1hr post 25
J/m2) treated cells serve as positive controls. (D) Immunoblots for Rap1 and Chk2 on SV40LT
immortalized MEFs with indicated genotypes, before and after treatment with Cre. γ-tubulin
serves as loading control. (E) Loss of Rap1 in Ku-deficient SV40LT immortalized MEFs does not
∆Rap1
, or vector control
alter the telomeric single-stranded DNA. MEFs expressing TRF2, TRF2
were analyzed using in-gel hybridization to MboI digested DNA before and 96 hours after
treatment with Cre. Left, hybridization signal with (CCCAAT)4 probe under native conditions; right,
hybridization signal with same probe after denaturation. Overhang signal was normalized to the
total telomeric repeat signal. Numbers represent the relative overhang signal as compared to
TRF2 plus Cre (set as 1).

52

2.3

Summary of findings
These data indicate that Rap1 functions at mouse telomeres to repress

HDR, which has the potential for generating shortened telomeres and can
promote telomerase-independent telomere maintenance. Furthermore, these
results underscore the functional compartmentalization within shelterin where
each subunit is dedicated to distinct functions. As previously reported, replication
of telomeric DNA is facilitated by TRF1
repression of ATR signaling

150,151

both ATM signaling and NHEJ

24

156,157

, TPP1/POT1 are required for the

, while TRF2 is the predominant repressor of

. The current data show that these functions of

TRF2 do not require Rap1. Instead, Rap1 is required to repress HDR.
Interestingly, this division of roles revealed that telomeres can undergo HDR
without being detected by the ATM and ATR kinase pathways. When HDR takes
place at telomeres lacking TRF2 or POT1a/b, DNA damage signaling results in
the formation of TIFs. In the case of Rap1 removal, however, the telomeres lack
detectable TIFs, yet are susceptible to HDR. Thus, the formation of DNA damage
foci at telomeres is not a prerequisite for HDR. How exactly Rap1 represses HDR
and the action of Ku in this repression remains to be determined.
It is of interest to recall that expression of the TRF2ΔB mutant allele leads
to stochastic t-loop loss, presumably because the basic domain of TRF2
stabilizes Holliday Junctions and restrains the action of HJ resolvases

172-175

.

However, if the basic domain of TRF2 cannot inhibit HJ resolution, a critical step
in the generation of T-SCEs, the question arises as to why T-SCEs are not
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observed in TRF2ΔB-expressing TRF2/Ku70-deficient cells

154

. One possibility is

that Rap1 bound to TRF2 may repress the formation of HJs so that T-SCEs will
not occur. For instance Rap1 and/or TRF2 may inhibit strand invasion into sister
chromatids, or Rad51 filament assembly, thereby preventing HJ formation and
potential exchange of sequence. In addition, it is possible that the basic domain
of TRF2 blocks branch migration of TRF2, thereby also repressing HJ formation
and preventing T-SCEs.
Rap1 was not required for the maintenance of several other features of
mouse telomeres including the amount of the single-stranded overhang, the level
of telomeric transcripts and the telomeric chromatin state and organization. In
budding yeast, Rap1 has been proposed to facilitate heterochromatin assembly
by recruitment of Sir3 and Sir4 that interact with the N-termini of histones H3 and
H4

231-233

. Despite a proximity-based screen identifying potential interactions

between Rap1 and histones H2A and H4

226

, Rap1 does not seem to play a role

in maintaining telomeric chromatin.
Surprisingly no gross aberrations in telomere length in Rap1 null cells
were observed either, although small differences may be difficult to discern due
to the long telomeres of mouse cells. Studies of Rap1’s involvement in telomere
length regulation may be more illuminating in human cells that have shorter
telomeres.
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Chapter 3: Elucidating the mechanism of HDR repression by
Rap1
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3.1

Introduction
How Rap1 represses HDR is not clear. It is possible that it functions by

recruiting another protein with its BRCT domain or MYB motif, which are
proposed to be protein-interaction domains (reviewed in

227

). Factors known to

interact with Rap1 include the Rad50 and Mre11 components of the MRN
complex

78

, which contributes to 5’ resection during HDR. However, the telomeric

overhang is not altered in Rap1/Ku70-deficient MEFs

19

, suggesting Rap1 does

not play a major role in modulating resection at telomeres. Therefore it seems
unlikely that Rap1 would inhibit telomeric HDR by limiting or preventing resection
by MRN. The Rap1/TRF2 complex also interacts with the protein scaffold SLX4
225

, which binds to a HJ resolvase Mus81/Eme1. It is possible that Rap1

modulates the activity of one of the nucleases in the SLX4 complex to interrupt
HDR.
In this chapter, Rap1 mutants were analyzed to determine which domains
of Rap1 were required for repression of T-SCEs. These experiments identified
the C-terminus of Rap1 as the important functional domain in the inhibition of
HDR. Further investigation suggested that TRF2/Rap1 complex formation was
necessary for HDR repression and preliminary experiments to assess the DNAbinding activity of this complex were conducted.
The repression of HDR also requires the presence of either of the two
POT1 proteins

155

. POT1a/b bind to single-stranded telomeric DNA and may

inhibit initiation of HDR by preventing loading of Rad51 onto ssDNA. In the

56

context of POT1a/b- and Ku70-deficiency, Rap1, which remains at telomeres, is
incapable of repressing HDR. The converse is true of POT1a/b that remain at
telomeres when Rap1 is deleted, but cannot inhibit HDR

19

. These data raise the

possibility that Rap1 and POT1 may act together to repress HDR. To investigate
whether Rap1 and POT1 are epistatic in their repression of HDR, an shRNA to
TPP1 was used to remove POT1 from telomeres in Rap1/Ku70-deficient cells.
No change in the level of T-SCEs would suggest that Rap1 and POT1 are
epistatic, possibly acting together at the same step. For instance, Rap1 and
POT1 may both interfere with Rad51 filament formation. Exacerbation of the
occurrence of T-SCEs would suggest that Rap1 and POT1 act on distinct, nonlinear aspects of homology-directed repair, for example HJ resolution by either
Mus81/Eme1 or GEN1.
The lack of DNA damage signaling in Rap1/Ku70-deficient MEFs also
provides a unique setting to study the consequences of ongoing HDR on
telomere maintenance. As mouse cells constitutively express telomerase, this
setting does not recapitulate ALT. However, the analysis of the long-term
consequences of combined deficiency of Rap1 and Ku may still provide insights
into the recombination-based mechanisms of telomere maintenance.
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3.2

Results

3.2.1 The C-terminus of Rap1 is required to repress telomeric HDR
MYC-tagged alleles of mouse Rap1 containing deletions of the relevant
motifs (BRCT, MYB, Coil) were constructed as illustrated in Figure 3.1A.
Determination of amino acid positions of domains was based on analogous
domain positions outlined in human Rap1

20,23

. Based on the crystal structure of

the hRap1 C-terminus in complex with a fragment of TRF2 (TRF2RBM, Rap1
binding motif, aa 275-316)

18

, the I318 residue in hRap1 was shown to be

required for its interaction with TRF2. Co-IPs of transfected proteins from 293T
cells showed that mutation of the analogous residue in mouse Rap1 (I312R)
disrupted the interaction with mouse TRF2 (Figure 3.1B).
Rap1 mutants were retrovirally expressed in Rap1F/FKu70-/- MEFs and
immunoblotting showed that most mutants were expressed at similar levels,
except for MYC-I312R, which was significantly overexpressed, and MYC-ΔBMC,
which was expressed weakly (Figure 3.1C). Rap1 protein levels are diminished
upon TRF2 depletion, yet surprisingly the Rap1 I312R mutant, which could not
bind TRF2, was overexpressed. Therefore, it seems that when Rap1 is not bound
to TRF2, the I312 residue is bound by another factor that targets it for
degradation. IF-FISH indicated that all mutants, except for MYC-I312R, localized
to telomeres (Figure 3.1D). IF for MYC-I312R showed diffuse staining throughout
the nucleus that disappeared upon extraction of nucleoplasmic proteins with

58

TritonX-100, indicating that the Rap1 I312R mutant was not associated with
chromatin. (Figure 3.1D). CO-FISH analysis after removal of endogenous Rap1
with Cre revealed that all but the MYC-I312R mutant repressed T-SCEs, thus
implicating the Rap1/TRF2 interaction in the inhibition of HDR (Figure 3.1E).
Furthermore, the data showed that the BRCT, MYB and coiled domains of Rap1
are not required for the repression of homology-directed repair, either individually
or together. Although the data argue against the N-terminus recruiting an HDRrepressing factor to telomeres, it is not excluded that the C-terminus of Rap1
binds to TRF2 and also recruits an HDR-repressor. However, since MYC-I312R
cannot localize to telomeres, it is possible that its deficiency in repressing HDR is
due to lack of telomeric recruitment of a factor involved in HDR inhibition. To
address this latter possibility, we devised a strategy to tether Rap1 to telomeres
in the absence of TRF2.
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Figure 3.1 The C-terminus of Rap1 is required to inhibit HDR. (A) Schematic of Rap1 domain
mutants. * indicates I312 to R mutation. ΔBMC, deletion of N-terminal 264 amino acids (aa),
Rap1 protein coding started at aa 265. ΔBRCT, deletion of N-terminal 106 aa, Rap1 protein
coding started at 107 aa. ΔMYB, deletion of aa 128-196, such that aa 127 was fused to aa 197.
ΔCoil, deletion of aa 231-264, such that aa 230 was fused to aa 265. The Rap1 antibody was
raised to full-length protein and detects multiple antigenic regions in the N-terminus of Rap1. (B)
293Ts were co-transfected with constructs as indicated and immunoprecipitated with a MYC
antibody. Inputs and IPs were detected by the MYC antibody (left) and the FLAG antibody (right).
MYC-TRF1 serves as a negative control for immunoprecipitation of FLAG-Rap1. (C) Immunoblots
F/F
-/of MYC-tagged constructs in (A) expressed in Rap1 Ku70 MEFs, detected with Rap1 antibody
(left) or MYC antibody (right). All constructs except ΔBMC contain an epitope(s) for the Rap1
antibody. n.s., non-specific band picked up by the Rap1 antibody. Running positions of constructs
F/F
-/on gel are indicated on the right. (D) IF-FISH of constructs in (A) expressed in Rap1 Ku70
MEFs. Red, IF for MYC; green, telomeric FISH, blue, DAPI DNA stain. White square shows
corresponding area enlarged below. (E) Quantification of T-SCEs. Bars represent averages from
three independent experiments (n~1000 chromosome ends each) and SDs. P values based on
Student’s two-tailed t-test.
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3.2.2 Rap1 does not inhibit HDR at telomeres lacking TRF2
Full-length TRF2 and a 41 amino acid fragment of TRF2 (TRF2RBM) bind to
Rap1 in vitro with similar affinities as determined by isothermal titration
calorimetry

18

. The sequence encoding these 41 amino acids was inserted into

MYC-tagged TRF1 (TRF1RBM) with the aim of allowing TRF1 to recruit Rap1 to
telomeres in the absence of TRF2 (Figure 3.2A). Expression of TRF1RBM in
TRF2F/FKu70-/- MEFs showed that endogenous levels of Rap1 could be restored
upon Cre-mediated deletion of TRF2 (Figure 3.2B). ChIP confirmed retention of
Rap1 at telomeres despite removal of TRF2, while the telomeric occupancy of
other shelterin components was not affected (Figure 3.2C-D). IF-FISH further
illustrated that both endogenous Rap1 and TRF1RBM co-localized with telomeres
(Figure 3.2E). IF for MYC displayed an unusual staining pattern of circular
patches in the nucleus due to non-specific association of the secondary antibody,
however magnification of insets show that MYC-tagged TRF1RBM localized to
telomeres (Figure 3.2E). Expression of TRF1RBM in TRF1-deficient MEFs
repressed the occurrence of fragile telomeres (Figure 3.3A-B), which are induced
upon loss of TRF1

156,157

. Thus, introduction of the RBM sequence into TRF1 did

not disrupt normal functions of TRF1 and allowed for the retention of Rap1 at
telomeres lacking TRF2. However, despite the presence of Rap1 at telomeres, TSCEs were not repressed when TRF2 was deleted from TRF2F/FKu70-/- MEFs
(Figure 3C-D), pointing to a requirement for the interaction between Rap1 and
TRF2 in the inhibition of HDR. Rap1 binding to TRF2 may be required for a
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conformational change of the complex that facilitates recruitment of an additional
protein involved in the repression of homology-directed repair. Alternatively,
Rap1 may change the DNA binding activity of TRF2, perhaps by changing its
affinity to DNA structures that resemble substrates for HDR, such as the telomere
terminus.
In addition to induction of telomere-sister chromatid exchanges, a low
percentage of alt-NHEJ mediated telomere fusions are also observed in
TRF2/Ku70-deficient MEFs

120

. Placement of Rap1 at telomeres by TRF1RBM did

not inhibit these fusions (Figure 3.3E) indicating that Rap1 does not play a role in
the repression of alt-NHEJ. In contrast to these results, another study shows that
tethering Rap1 to HeLa (a human cervical carcinoma cell line) telomeres by a
fungal telomere-binding domain can repress c-NHEJ-mediated fusions when
TRF2 is depleted

160

. It remains to be seen whether retention of Rap1 by

TRF1RBM can inhibit c-NHEJ mediated telomere fusions in TRF2-null MEFs.
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Figure 3.2 Tethering Rap1 to telomeres in the absence of TRF2. (A) Schematic illustrating
RBM
allele. 41 aa encoding RBM was inserted into TRF1 at position aa
composition of the TRF1
278. This did not interfere with the Bloom (BLM) helicase interaction sites shown in purple, or
disrupt any other known interaction or nuclear localization signal. (B) Immunoblot showing
RBM
F/F
-/in TRF2 Ku70 MEFs and levels of Rap1 before and 96 hours after
expression of TRF1
RBM
at
deletion of TRF2 with Cre. (C) ChIP for shelterin components and MYC-tagged TRF1
telomeres before and 96 hours after deletion of TRF2. Dot blot was probed with TTAGGG
repeats. (D) Relative telomeric ChIP signals obtained as in (C) were expressed as the ratio of
signal in minus and plus Cre samples. Minus Cre set to 1. Values with error bars represent
averages of two experiments. Error bars represent SEM. (E) Combined IF for MYC (orange) to
RBM
detect TRF1 , for Rap1 (red) and FISH for telomeres (green). Blue in merged image: DAPI
DNA stain. White square corresponds to area of enlarged image below.
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RBM

Figure 3.3 Rap1 cannot repress HDR in the absence of TRF2. (A) Immunoblot of TRF1
F/F
expressed in TRF1 Cre-ERT2 (tamoxifen inducible Cre expression) MEFs where endogenous
TRF1 was deleted by treatment with 4-hydroxytamoxifen (4-OHT). (B) Quantification of fragile
telomeres of cells in (A) before and 96h after treatment with 4-OHT. Bars represent mean values
of three independent experiments with SDs. P values derived from two-tailed Student’s t-test. (C)
RBM
F/F
-/COFISH of TRF1 -expressing TRF2 Ku70 MEFs before and 96 hours after treatment of
Cre. White arrows point to T-SCEs. (D) Quantification of T-SCEs as shown in (C). Bars represent
mean values of three independent experiments with SDs. P values derived from two-tailed
Student’s t-test. (E) Quantification of chromosome fusions on metaphase spreads of cells in (D).
Bars represent mean values of three independent experiments with SDs. Student’s t-test
F/F
-/Ku70 MEFs expressing vector
indicated lack of significance between Cre-treated TRF2
RBM
control or TRF1 .
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3.2.3 Rap1 confers an increase in TRF2 DNA binding affinity.
To test the hypothesis that Rap1 changes the interaction of TRF2 with
certain DNA substrates, nickel-affinity purifications of baculovirus-expressed HisRap1, His-TRF2, and the His-Rap1/TRF2 complex were performed (Figure 3.4A).
For purification of the Rap1/TRF2 complex, His-hRap1 and hTRF2 were coexpressed in Sf9 insect cells. Immunoblotting of the co-purified Rap1/TRF2
complex showed the expected 1:1 stoichiometry of Rap1 and TRF2 (Figure
3.4B). Electrophoretic mobility shift assays (EMSAs) with a duplex telomeric
substrate with 12 repeats showed the Rap1/TRF2 complex had a slight increase
in DNA binding affinity (less than 2-fold) over TRF2 alone (Figure 3.4C). Mixing of
separately purified Rap1 and TRF2 did not result in this improved binding affinity
and the pattern of the shifted probe looked very similar to TRF2 alone,
suggesting that Rap1/TRF2 complex formation was not efficient in vitro (Figure
3.4C). Analysis of binding to a ds-ss ‘junction’ indicated that the co-purified
complex bound to the junction substrate with a higher affinity than TRF2 alone
(Figure 3.4D). Binding of TRF2 to the junction probe was variable with an affinity
ranging from 2.5- to 6-fold less than that of the Rap1/TRF2 complex. Despite the
ability of Rap1/TRF2 to bind to the junction probe better than TRF2 alone, its
affinity for a telomeric junction was very similar to its affinity for duplex telomeric
DNA. Therefore, while Rap1 clearly increases the DNA binding affinity of TRF2, it
is unclear whether it is this activity of Rap1 that confers its inhibition of HDR. The
length of the telomere tract did not affect Rap1/TRF2 binding ability, as EMSAs
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with a duplex DNA substrate with three telomere-repeats (like the junction probe)
did not show a change in DNA-binding affinity. Rap1 has previously been shown
not to bind duplex telomeric DNA

20

and similarly did not exhibit any DNA binding

to the junction probe (Figure 3.4D). Taken together these data suggest that Rap1
binding to TRF2 improves its ability to bind telomeric DNA. However, a significant
difference was not observed in the binding affinity of Rap1/TRF2 to a ds-ss
telomere junction relative to duplex telomeric DNA. Therefore it remains unclear
whether Rap1 inhibits HDR by altering the DNA binding activity of TRF2.

3.2.4 HDR is not aggravated by dual absence of Rap1 and POT1
To test whether Rap1 and POT1 repress HDR at the same step, I created
and analyzed cells in which both Rap1 and POT1 were removed from telomeres.
An shRNA to TPP1 was used to deplete POT1a/b from telomeres in
Rap1F/FKu70-/- MEFs. As a control, TPP1 was also depleted in Rap1F/FKu70+/MEFs, where the presence of one allele of Ku is sufficient to inhibit T-SCEs. The
level of TPP1 knockdown could not be assessed by immunoblotting due to lack
of a good antibody for mouse TPP1. However, the TPP1 shRNA was effective in
POT1a/b removal as indicated by the induction of TIFs (Figure 3.5A-B) as well as
the appearance of T-SCEs in Ku70-deficient cells (Figure 3.5D-E). Deletion of
Rap1 with Cre (Figure 3.5C) in TPP1-depleted cells did not exacerbate the TSCE phenotype (Figure 3.5D-E). In fact the levels of T-SCEs observed in a Ku70deficient background when Rap1 or POT1 alone were depleted, was very similar
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to telomeres lacking both Rap1 and POT1. Telomeres remained shielded from
HDR when Rap1 and POT1 were removed in Ku70-proficient cells. These data
suggest that Rap1 and POT1 act together to repress HDR.
One caveat to consider with the interpretation of these results is whether it
is possible to observe an exacerbation of the T-SCE phenotype. Theoretically,
assuming HDR intermediates can be equally shuttled into pathways that dissolve
the Holliday junction or resolve it resulting in crossover, the maximal number of
T-SCEs we would expect to detect is 50%. Current levels of T-SCEs observed
are rarely above 15%. Various efforts to knockdown BLM or TOP3α to remove
the dissolution arm of HDR and skew resolution of HDR intermediates into
crossovers were unsuccessful, therefore it remains to be seen what the threshold
of detection for T-SCEs is.
Despite this caveat, these results raise the possibility that Rap1 and POT1
repress HDR as a subcomplex of shelterin. Indeed it has been shown that TRF2
and POT1 are capable of forming a detectable complex

21,152,185,234

. However,

coimmunoprecipitation experiments failed to detect a stable interaction between
MYC-POT1a or –b and FLAG-Rap1 (Figure 3.5F).
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Figure 3.4 Rap1 confers an increase in the telomere binding affinity of TRF2.
(A) Coomassie stained SDS-PAGE gels of purified His-tagged proteins as indicated. 2-fold serial
dilutions of purified protein and Bovine serum albumin (BSA) were run on the same gel to quantify
protein amounts. (B) Immunoblotting of quantified protein amounts to calculate stoichiometry of
Rap1 and TRF2 in the co-purified sample. (C) Top, schematic of probe (restriction fragment
containing 12 TTAGGG repeats) used for EMSAs below. Bottom, EMSAs with 2-fold serial
dilutions of indicated proteins; probe, no protein added. Dissociation constants (Κd) calculated
below. Values for co-purified and TRF2 are mean of three experiments with SDs. (D) Top,
schematic of probe with 3 TTAGGG repeats, a 3’ overhang containing the minimal binding site for
POT1 (5’-GGTTAGGGTTAG-3’), and a natural telomere end (ATC-5’). Bottom, EMSAs with probe
above using 2-fold serial dilutions of indicated proteins; probe, no protein added. Dissociation
constant (Κd) calculated below. Value for co-purified is mean of three experiments with SDs; n.d.,
not determined.
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Figure 3.5 No exacerbation of T-SCE levels upon removal of Rap1 and POT1. (A) TIF assay
F/F
-/F/F
+/on Rap1 Ku70 or Rap1 Ku70 MEFs treated with Cre and or a TPP1 shRNA as indicated for
96 hours. White square indicates area enlarged below. (B) Quantification of TIF-positive cells as
in (A). Cells with ≥ 10 TIFs were considered TIF-positive. Bars represent mean values of three
independent experiments with SDs. (C) Immunoblot for Rap1 in cells as described in (A). (D) COFISH assay on cells as described in (A). White arrows indicate T-SCEs. (E) Quantification of COFISH in (D). Bars represent mean values of three independent experiments with SDs. P-values
calculated based on Student’s t-test. (F) MYC-immunoprecipitation from 293T cells co-transfected
ΔRap1
was used as
with MYC-tagged constructs as indicated and FLAG-tagged Rap1. MYC-TRF2
a negative control and MYC-TRF2 was used as a positive control for interaction with Rap1.
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3.2.5 Deletion of Rap1 and TRF1 does not induce T-SCEs
TRF1 loss results in inefficient replication of telomeric DNA

156

and

potentially introduces replication intermediates that are susceptible to resolution
by homology-directed repair. However, T-SCEs are not observed when telomeres
lack TRF1, possibly due to repression of HDR by Ku70/80. Indeed, preliminary
analysis of MEFs lacking TRF1 and Ku80 showed an induction of T-SCEs
(Figure 3.6A), suggesting that telomeres are also vulnerable to HDR during DNA
synthesis.
Mass spectrometry and ChIP experiments using human cells have
implicated shelterin components TRF1, TRF2 and Rap1 in interacting with and
potentially recruiting Ku to telomeres

78, 265, 283

, although Ku has also been shown

to bind directly to telomere repeats in vitro 284. To explore potential redundancy in
the recruitment of Ku to telomeres, we decided to delete both Rap1 and TRF1
from telomeres. If T-SCEs were observed in Rap1/TRF1 null MEFs, this would
suggest that Ku is unable to repress HDR in this setting. Alternatively, removing
both Rap1 and TRF1 could lead to an increase in telomere substrates vulnerable
to HDR and result in T-SCEs regardless of whether co-repression of HDR by Ku
was functional or not.
Analysis of metaphases lacking Rap1 and TRF1 in a Ku-proficient setting
showed an increase of fragile telomeres and telomere sister associations which
are characteristic of TRF1 loss (Figure 3.6B-C). Despite the presence of telomere
replication problems, no induction of T-SCEs was observed (Figure 3.6C),
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suggesting that Ku was still able to repress HDR. A low level of telomere fusions
were also detected in MEFs where Rap1 and TRF1 had been deleted (Figure
3.6C), potentially due to minor destabilization of TRF2 binding to telomeres.

Figure 3.6 Ku represses T-SCEs in TRF1 null cells, as well as in MEFs lacking both Rap1
and TRF1. (A) Quantification of T-SCEs (left) and telomere sister associations (right) on
metaphase spreads, before and 96 hours after treatment with Cre. Genotypes as indicated. (B)
Western blot of two littermate controls with genotypes as indicated, before and 96 hours after
treatment with Cre. Antibodies used for detection of proteins are indicated on left. (C)
Quantification of aberrant structures on metaphase spreads in Rap1F/F TRF1F/F MEFs before
and 96 hours after treatment with Cre. Data represents averages and standard deviations from
analysis of three independently derived cell lines.
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3.2.6 HDR is repressed in late-passage Ku70-deficient MEFs
The induction of homology-directed repair in absence of DNA damage
signaling and cell cycle arrest in Rap1/Ku70-deficient MEFs allowed examination
of the consequences of unbridled HDR on telomere maintenance. Rap1F/F Ku70-/(or Rap1F/Δ Ku70-/-) MEFs were isolated and immortalized with SV40LT. The
immortalization process is variable and takes approximately 15 to 20 PDs for
cells to escape crisis and proliferate at a steady pace. The number of PDs cells
undergo during immortalization is a reproducible estimate, but cannot be exactly
calculated due to cell death or senescence that primary MEFs undergo during the
immortalization process. After immortalization, at approximately PD 20,
Rap1F/FKu70-/- (or Rap1F/ΔKu70-/-) MEFs were further cultured to 70 PDs with and
without Cre treatment (Figure 3.7A-B). Cells were harvested at various timepoints to assess the level of T-SCEs. Surprisingly, T-SCE events began to
diminish as early as PD 30 and were reduced to basal levels similar to Rap1proficient cells by PD 50 (Figure 3.7C). T-SCEs were also no longer induced
when Rap1 was deleted from late passage Rap1F/F Ku70-/- showing that Ku70deficient MEFs exhibit downregulation of telomeric HDR when cultured
extensively.
To determine whether HDR was downregulated in general or just at the
telomere, efforts were made to use a transient reporter assay developed in the
Jasin lab

171

that assesses HDR-mediated repair events of a break induced by

expression of I-SceI (a site-specific endonuclease). However this assay did not
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work robustly in MEFs, due to difficulty in achieving high transfection efficiencies
and minimal cell death.

Figure 3.7 HDR is repressed in late-passage Ku70-deficient MEFs. (A) Growth curve of
F/F
-/Rap1 Ku70 MEFs with and without deletion of Rap1 by Cre. (B) Western blot indicating Rap1
levels in the two cell lines shown in (A) at the indicated PDs. (C) CO-FISH analysis of Ku70
deficient MEFs with or without Rap1 at the indicated PDs. White arrows point to T-SCE events.
Quantification of chromosome ends with T-SCEs for three independent experiments is listed
under corresponding CO-FISH panels.
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3.3

Summary of findings
The data presented here show that Rap1 requires its interaction with

TRF2 to repress HDR. Recruitment of Rap1 to telomeres by TRF1RBM in the
absence of TRF2 did not prevent T-SCEs. It is possible however, that
experimentally induced binding of Rap1 to TRF1RBM may disrupt Rap1’s
interaction with another factor required for repression of HDR. Additionally, the
specific localization of Rap1 at telomeres by TRF1RBM may be subtly, yet
impactfully different compared to its placement byTRF2.
The Rap1/TRF2 complex may bind to a protein involved in HDR inhibition
that Rap1 alone or TRF2 alone may be unable to bind to. Alternatively, Rap1
may enhance the DNA binding affinity of TRF2 to HDR substrates and prevent
loading of components required for repair. Preliminary gel-shift assays indicated
that Rap1 may enhance the overall binding affinity of TRF2 to telomeric DNA, but
this effect was minor and it is unclear whether it would be physiologically
relevant. However, one report showed that the Rap1/TRF2 complex binds to dsss telomere junctions 10-fold better than duplex DNA

235

. The discrepancy

between this study and the results reported here could be due to changes in the
activity or oligomeric state of the purified proteins, as well as the different
substrates used. In addition, another study reported Rap1 conferred no
advantage to TRF2 to bind ds-ss telomere junctions, but instead improved the
specificity of TRF2 binding to telomeric DNA 236.
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Rap1 and POT1a/b seem to inhibit HDR via the same pathway as no
increase in the number of T-SCEs was observed when Rap1 and POT1a/b were
all removed from telomeres in a Ku70-deficient setting. Further assessment of
Rap1/TRF2 DNA-binding needs to be conducted in the context of the shelterin
complex, as POT1 binding to the overhang together with Rap1/TRF2 binding to
the ds-ss junction may contribute to the repression of telomeric HDR.
Lastly, the surprising finding that Ku70-deficient cells eventually
downregulate HDR suggests that when Ku is unable to inhibit HDR other factors
may be enlisted to regulate HDR. Efforts to determine whether this repression of
HDR was global or telomere-specific have thus far been unsuccessful and
warrant further study.
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Chapter 4: TALEN gene knockouts of human Rap1
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4.1

Introduction
Two discrepancies exist concerning the function of Rap1 in mammals. In

vitro, human Rap1 can block NHEJ when it binds to TRF2 loaded on an endjoining substrate

213

. In vivo, a Rap1-fusion protein can reduce telomere fusions

when it is tethered to telomeres that are depleted of TRF2 160. On the other hand,
mouse cells lacking Rap1 show no telomere fusions and Rap1-deficient mice are
alive and fertile

19,220

. The only telomere deprotection phenotype in Rap1-

deficient mouse cells is a propensity for telomere-telomere recombination when
Ku70/80 are also absent 19.
In addition, it is unclear whether Rap1 has a conserved role in telomere
length homeostasis in mammals. In support of a role in telomere length control,
shRNAs to human Rap1 induce telomere lengthening
of several Rap1 truncation mutants

23

78

, as does overexpression

. Furthermore, overexpression of Rap1

mutants lacking its BRCT domain or MYB motif exhibit diminished telomere
length heterogeneity, suggesting Rap1 also has a role in regulating distribution of
telomere length. However, Rap1 knockout mice show no change in telomere
length, even after three generations 19.
To determine the function(s) of human Rap1, Transcription Activator Like
Effector Nucleases (TALENs) were used to knockout the Rap1 gene. Analysis of
several independent Rap1-deficient cell lines demonstrated that human Rap1
was not required for telomere protection, telomere length regulation, and other
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aspects of telomere function. Instead, changes were observed in the transcription
of several genes upon loss of Rap1.

4.2

Results

4.2.1 Efficient TALEN-mediated knockout of human Rap1
Similar to the mouse, the human Rap1-encoding gene (TERF2IP, referred
to as Rap1) shares its promoter region with the essential KARS (lysyl-tRNA
synthetase) gene located just upstream of exon 1 (Figure 4.1A). To avoid
disrupting the KARS gene, a targeting strategy analogous to the one used for
mouse Rap1

19

was implemented and TALENs were employed to delete exon 2.

Deletion of exon 2 should result in an mRNA encoding a 226 aa ORF that ends
prematurely in a stop codon at the beginning of exon 3. As exon 3 encodes the
TRF2-binding domain, the truncated Rap1 protein is not expected to localize to
telomeres. Taking advantage of the small size of exon 2 (125 bp) and anticipated
resection of TALEN-induced DSBs

237,238

, a neomycin or blasticidin donor

construct was designed containing 5’ and 3’ arms homologous to the surrounding
introns. HDR using the donor construct should result in deletion of exon 2 and
insertion of the neomycin cassette (Figure 4.1A).
Rap1 was targeted in two near-diploid cancer lines (HCT116 colorectal
carcinoma and HT1080 fibrosarcoma), a subclone of the near-triploid cervical
carcinoma HeLa cell line (HeLa1.3

22

), the diploid ARPE-19 retinal pigment
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epithelial cell line, and primary BJ fibroblasts transformed with SV40LT. With the
exception of BJ-SV40LT, all cells expressed telomerase. For HCT116, HT1080,
and ARPE-19 cells, neomycin resistant clones were obtained, analyzed by PCR,
and then evaluated by Southern blotting to verify the correct neomycin insertion
(Figure 4.1B-C). For HeLa1.3 and BJ-SV40LT, the blasticidin donor construct
was used and clones were analyzed by immunoblotting for Rap1. These
analyses identified clones that lacked the wild type Rap1 gene and expressed no
detectable Rap1 protein (Figure 4.1C-D). Polypeptides representing the
remaining ORF of the targeted Rap1 gene were not detected (Figure 4.2A-C),
perhaps due to nonsense-mediated decay.
Unexpectedly, immunoblotting revealed the complete loss of Rap1 in
heterozygous clones with one neo insertion (Figure 4.1B-C). Telomeric ChIP of
two such clones (HT1080 c21 and HeLa1.3 c28) confirmed that Rap1 was absent
from telomeres (Figure 4.2D-G). Sequencing revealed small deletions close to
the TALEN site in these and other Rap1-deficient clones with only one neocontaining Rap1 gene (Figure 4.3A-B). Most mutations had ablated Rap1 by
deleting the exon 2 splice acceptor site or had created a frame-shift mutation,
indicating that errors generated during NHEJ had inactivated the Rap1 gene
(Figure 4.3C). As a result, the frequency of the Rap1 knockouts (KOs) is much
higher than deduced from PCR genotyping. Taking the deleterious repair events
into account, the ablation of Rap1 occurred at 20-65% efficiency in HCT116,
HT1080, and ARPE-19 cells (Figure 4.3D). The HCT116 cells showed the
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highest KO frequency consistent with their propensity for HDR (reviewed in

239

).

The actual KO frequency is probably even higher as only clones with a neo
cassette in the Rap1 gene were analyzed.
The high KO frequency allowed screening of HeLa1.3 and BJ-SV40LT
clones by Rap1 immunoblotting. Sequencing of Rap1-negative HeLa1.3 clones
revealed that all three alleles in these clones contained inactivating mutations
near the TALEN cut site (Figure 4.3B). Prolonged culturing of clones in blasticidin
resulted in cell death, suggesting that the pEF blasticidin cassette did not confer
long-term resistance. The KO frequency was lower in BJ-SV40LT fibroblasts with
only one blasticidin-resistant clone showing absence of Rap1 protein. This clone
was not analyzed because it perished in telomere crisis, as did many of the
Rap1-proficient BJ-SV40LT clones.
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Figure 4.1 TALEN-mediated inactivation of the gene for human Rap1. (A) Schematic of
human Rap1, the Rap1 locus, the targeting construct, and the resulting knockout allele. F1, R1,
and R2neo: PCR primers for genotyping. Arrows in bold: TALEN binding and cut sites. (B)
Southern blot of EcoRI (RI)- or BglII/EcoRV (RV)-digested genomic DNA from targeted HT1080
clones. Probe shown in (A). (C) PCR genotyping of the Rap1 gene and western blotting for Rap1
in the indicated clones. +, WT allele; Δ, targeted allele; mut, mutation resulting in loss of Rap1.
(D) Immunoblotting of protein from targeted homozygous and heterozygous HCT116 clones
showing absence of Rap1 in a large proportion of heterozygous clones. Genotypes indicated
below.
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Figure 4.2 Loss of Rap1 in targeted clones. (A) Immunoblots of HCT116 and HT1080 KO
clones probed with anti-hRap1 showing the absence of detectable truncated Rap1 proteins. (B)
Schematic of retroviral constructs expressing FLAG-tagged exon 1 (ex 1) and FLAG-tagged exon
3 (ex 3). (C) Immunoblotting for the expression of constructs in (B) in HT1080 KO and WT clones.
The protein fragment encoded by exon 1 is expressed and detected by the Rap1 antibody. The
protein fragment encoded by exon 3 contains epitopes that the Rap1 antibody can recognize, but
lack of detectable signal indicates that it is not expressed. (D) Telomeric ChIP of WT and targeted
HT1080 clones. Duplicate dot-blots were probed for telomeric or Alu repeats. (E) Average
percentage of telomeric DNA recovered in ChIPs with the indicated antibodies (two independent
experiments). Error bars: SEMs. (F) Telomeric ChIP of HeLa 1.3 WT and KO cells. (G)
Quantification of the percent of telomeric DNA recovered in each ChIP.
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Figure 4.3 TALEN-induced mutations in the Rap1 locus. (A) Schematic illustrating TALEN
binding sites, their predicted cutting site (grey arrows), the pyrimidine tract, splice acceptor (SA),
and the location of exon 2 in the Rap1 locus. A short repeat (underlined in grey) is frequently
mutated in the mutant alleles. (B) Relevant sequences of the indicated clones. Predicted
consequences of the mutations are indicated on the right. (C) Schematic illustrating NHEJ and
HDR after TALENs cutting. (D) Table indicating number of Rap1 knockout clones acquired and
the genetic alterations in Rap1.
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4.2.2 Rap1-deficient cell proliferate and maintain fully protected telomeres
The Rap1-deficient cell lines proliferated normally (Figure 4.4A) and
lacked a significant level of TIFs (Figure 4.4B-C), indicating that removal of Rap1
from telomeres does not result in a DNA damage response. Cells lacking Rap1
also did not show a significant induction of DSB repair at telomeres. Metaphase
spreads of Rap1 KOs lacked chromosome end fusions, a read-out for telomeric
NHEJ (Figure 4.5A-B). CO-FISH to monitor HDR-mediated T-SCEs established
that recombination remained repressed at telomeres (Figure 4.5C-D). Analysis of
telomere-sister chromatid exchanges in cells lacking Rap1 was conducted in a
Ku-proficient background. Similar to the mouse, human Ku70/80 are also
required to repress telomere recombination. However, unlike the mouse, deletion
of Ku70/Ku80 is lethal in human somatic cells

240,241

, thus it was not possible to

test a setting where both Rap1 and Ku70/80 were deleted. While the contribution
of human Rap1 to the repression of HDR in the context of Ku70/80-deficiency
remains to be determined, our data indicate that human telomeres remain
protected from NHEJ and HDR in absence of Rap1.
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Figure 4.4 Rap1-deficient cells proliferate and do not induce DNA damage signaling.
(A) Growth curves of WT and Rap1 KO HT1080 clones. (B) TIF assay on WT and KO HeLa1.3
clones. Green, telomeric FISH; red, IF for 53BP1; blue, DNA (DAPI). (C) Quantification of TIFs
assay (see (B)). Error bars: SDs of three independent experiments (n≥100 nuclei per clone). P
values from a two-tailed paired t-test combining WT and KO datasets. n.s.: not significant.
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Figure 4.5 Telomere protection in Rap1-deficient cells. (A) Metaphase chromosomes from
the indicated WT and Rap1 KO cells. Green, telomeric FISH; blue, DNA (DAPI). (B)
Quantification of telomere fusions, detected as in (A), in the indicated clones. P values from a
two-tailed paired t-test on combined WT and KO datasets. (C) CO-FISH analysis on the indicated
WT and KO HeLa clones. (D) Table showing the percentage of telomeres showing T-SCEs as
assayed in (C) in the indicated clones. P value from unpaired two-tailed t-test.
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4.2.3 Unaltered telomere length dynamics in absence of Rap1.
To determine whether Rap1 affected telomere length homeostasis, two
HT1080 Rap1-deficient clones were cultured for 50 PDs alongside two Rap1proficient clones selected for their matching telomere lengths (Figure 4.6A). All
clones exhibited a mild increase in telomere length (Figure 4.6B). The two Rap1deficient clones lengthened their telomeres at a similar modest rate (1-2 bp/PD)
whereas the two Rap1-proficient clones differed in the rate of telomere
lengthening (28 and 4 bp/PD) (Figure 4.6B). Given the clonal variation and small
differences in telomere length changes, the removal of Rap1 did not appear to
have a strong effect on telomere length dynamics in HT1080 cells.
Similarly, Rap1 did not affect the telomere length dynamics of HCT116
clones (Figure 4.6C). Two Rap1-deficient clones showed telomere shortening at
variable rates (-3 to -32 bp/PD). Given that the telomere shortening in the
parental cells (-27 bp/PD) is similar to that of one of the Rap1-deficient clones
(c10), it can be concluded that Rap1 did not strongly affect telomere dynamics in
HCT116 cells either.
Finally, three Rap1-deficient ARPE-19 clones (c26, c25, and c30) showed
wide variations in telomere dynamics, ranging from slight shortening (-18 bp/PD)
to slight elongation (9 and 16 bp/PD) (Figure 4.6D). The single Rap1-proficient
clone (c23) showed telomere shortening at a rate of -34 bp/PD. Thus, there is
considerable variability in the telomere dynamics in ARPE-19 clones but no
consistent effect of Rap1 deletion.
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Given the lack of consistent shortening or lengthening phenotypes in
multiple Rap1 knockouts, the simplest interpretation is that Rap1 does not play a
major role in telomere length regulation. Deletion of Rap1 also did not induce an
obvious change in the telomere length heterogeneity (Figure 4.6A and 4.7A),
which was affected by Rap1 mutants in overexpression studies

20

. Removal of

Rap1 from several cell lines also did not appear to affect the 3’ telomeric
overhang. The amount of ss telomeric DNA was determined by in-gel
hybridization of a labeled C-strand telomeric repeat probe to native telomeric
restriction fragments. Quantification of normalized single-stranded telomeric DNA
signals indicated that Rap1 status had no significant impact on the 3’ overhangs
in HT1080, HCT116, and ARPE-19 cells (Figure 4.7A-B).
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Figure 4.6 Rap1 knockouts exhibit no systematic changes in telomere length. (A) Southern
blot of telomeric restriction fragments from two WT and two KO HT1080 clones at the indicated
PDs.(B-D) Curves of average telomere lengths at indicated PDs in HT1080, HCT116, and ARPE19 clones, respectively.
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Figure 4.7 Loss of Rap1 does not affect telomere structure. (A) Telomeric DNA analysis of
WT and KO clones in three different cell lines. Top, in-gel detection of native telomeric restriction
fragments with a C-strand telomeric probe revealing the G-strand overhang signals; bottom,
same gel rehybridized after in situ denaturation of the DNA, revealing the total telomeric DNA in
each lane. Three biological replicates of each cell line were run adjacent to each other on the
same gel. (B) Overhang signals were normalized to total telomeric signals in each lane and
plotted as a ratio compared to the WT overhang signal of the corresponding cell line. Error bars
represent SDs. Lack of statistical significance derived from two-tailed paired t-tests using the
three independent experiments conducted with each cell line.
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4.2.4 Telomeric positioning in Rap1 null cells
To determine whether Rap1 is involved in the peripheral positioning of
telomeres in newly formed G1 cells

219

, mitotic shake-off was used to analyze

HeLa1.3 daughter cells in early G1. HeLa cells were used due to the ease of
detection of their long telomeres, and the same method of telomere position
analysis had been previously conducted in HeLa cells

219

, thereby enabling a fair

comparison to published data.
Using Lamin A to mark the nuclear envelope (NE) and FISH to visualize
telomeres, the subnuclear position of the telomeric signals was determined and
compared between Rap1-proficient and -deficient cells (Figure 4.8A-B). The
distribution of telomeres in the nucleus and median distance from the nuclear
envelope was similar for two Rap1-proficient and -deficient clones in two
independent experiments. Moreover, the percentage of telomeres present in a
zone defined arbitrarily as the nuclear periphery (within 10% distance from the
NE) was also similar regardless of Rap1 status, illustrating that Rap1 is not
required for the more peripheral positioning of telomeres in early G1.
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Figure 4.8 Effects of Rap1 on telomere position. (A) Combined IF for lamin A (red) and FISH
for telomeres (green) in early G1 nuclei of WT and Rap1 KO HeLa1.3 clones. The scale in one
nucleus indicates how the position of the telomeric signals was determined. Blue: DAPI DNA
stain. (B) Distance of telomeres from nuclear envelope (NE) in arbitrary units. For each nucleus
imaged in a single plane, the ratio between the distance of each telomere from the center and the
radius (center to NE) was plotted. Median distance for each clone is indicated by horizontal line.
% telomeres at periphery reflects telomeres within 10% of the distance from the NE. Two
independent experiments for each clone are shown.
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4.2.5 No change in telomeric chromatin or transcription upon Rap1 loss
Mammalian telomeres contain nucleosomes and epigenetic marks that are
characteristic of heterochromatin, such as H3K9me3, H4K20me3 and the loading
of heterochromatin protein 1 (HP1, reviewed in

228

). Rap1 also had no detectable

effect on general markers for the chromatin status at telomeres, as evidenced by
ChIP for methylation of H3K9, acetylation of H4, and HP1α, HP1β and HP1γ
(Figure 4.9A-B). In addition there was no significant effect of Rap1 on the
abundance of the telomeric lncRNA TERRA (Figure 4.9C-D). This finding is
consistent with the unaltered TERRA levels after deletion of mouse Rap1 19.
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Figure 4.9 No change in telomeric chromatin or transcription in Rap1-deficient cells.
(A) ChIP for modified histones at telomeres in WT and Rap1 KO cells. Duplicate blots were
probed for telomeric DNA or Alu repeats. (B) Relative telomeric ChIP signals obtained as in (A)
were expressed as the ratio of signal in KO and WT clones (WT set to 1). Values represent
averages of two experiments. Error bars: SEMs. (C) Northern blot hybridized with a telomeric
probe showing TERRA levels of Rap1 WT and KO clones in the HT1080, HCT116 and ARPE-19
cell lines. U2OS serves as a positive control for TERRA expression. Ethidium bromide staining of
ribosomal RNA serves as a loading control. (D) TERRA signals were normalized using the 18S
ribosomal RNA and plotted as a ratio compared to the WT TERRA signal of the corresponding
cell line. Error bars represent SDs. Two-tailed unpaired t-tests of 3 independent experiments
illustrates lack of statistical significance between Rap1 WT and KO TERRA expression levels.
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4.2.6 Rap1 affects transcriptional regulation
Mouse Rap1 localizes to over 8600 gene-associated loci, affecting
transcription of numerous genes
loci

223

220-222

, while human Rap1 is found at ~63 gene

. To query the effect of Rap1 on the transcriptome, microarray profiling

was performed on seven Rap1 WT and KO clones derived from three different
cell lines, ARPE-19, HT1080 and HCT116. A number of differentially regulated
genes were identified (Tables 4.1-4.3). The three Rap1-regulated genes in the
ARPE-19 cells (LHX2, LRRC17 and CDO1) were validated by quantitative RTPCR (qRT-PCR) and their response to Rap1 deletion was further confirmed on
an additional ARPE-19 Rap1 KO clone (c26) (Figure 4.10A-C). The Rap1regulated genes varied between the different cell lines, most likely due to the
different origins of the cell lines. Gene ontology analysis was uninformative,
because of the low number of genes identified by this limited analysis. However,
one Rap1-regulated gene in the HT1080 cells was among the human Rap1associated loci in the HT1080-derived HTC75 cell line

223

. Taken together, these

data are consistent with a role for Rap1 in transcriptional control in human cells.
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Table 4.1 Microarray expression analysis for ARPE-19.
a

Cell Line
Gene (chromosome) [LogFC]
KO v WT
LHX2 (chr9)
LRRC17 (chr7)
CDO1 (chr5)
c25 v c23
-3.3
-5.1, -3.4
-3.5
c30 v c23
-2.7
-5.1, -3.4
-3.8
c25 v par
-4.2
-4.6, -3.1
-3.3
c30 v par
-3.7
-4.5, -3.0
-3.5
a
,Multiple LogFC values reflect data from multiple probes for the corresponding gene.

Table 4.2 Microarray expression analysis for HT1080.
Gene (chromosome) [LogFC]a

Cell Line
KO v WT

ATP9A
(chr20)

CDCP1b
(chr3)

c8 v c2
c21 v c2
c8 v c9
c21 v c9

3.0
3.1
3.8
3.9

3.4, 1.8, 2.5, 3.7, 1.9, 2.4, 3.0
3.6, 1.8, 2.3, 3.9, 1.8, 2.3, 2.8

CYP2J2 FAIM3
(chr1)
(chr1)
2.0
2.2
1.6
3.5

-3.4
-3.6
-2.0
-2.2

MGC
39900
-2.1
-2.3
-2.7
-2.9

NELL2
(chr12)

PTGR1
(chr9)

TERF2IP
(chr16)

3.0
2.2
2.9
2.2

2.0, 1.7
2.1, 1.9
2.0, 1.7
2.1, 1.9

-2.9
-2.3
-2.9
-2.3

a

b

,Multiple LogFC values reflect data from multiple probes for the corresponding gene. CDCP1
223
was identified as a Rap1 associated locus by ChIP-seq in a subclone of HT1080	
   .

Table 4.3 Microarray expression analysis for HCT116.
a

Cell Line
Gene (chromosome) [LogFC]
KO v WT
BMP4 (chr14)
SLC2A3 (chr12)
SUSD2 (chr22)
c10 v c15
-2.0
-3.4
-2.6
c21 v c15
-2.1
-2.7
-2.2
c28 v c15
-1.9
-2.3
-2.1
c10 v c20
-2.0
-2.7
-2.0
c21 v c20
-2.0, -2.5
-2.0
-1.6
c28 v c20
-1.8
-1.5
-1.5
c10 v c23
-1.8
-2.9
-2.8
c21 v c23
-1.9, -2.4
-2.1
-2.5
c28 v c23
-1.7
-1.7
-2.3
a
,Multiple LogFC values reflect data from multiple probes for the corresponding gene.
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Figure 4.10 Validation of Rap1 as a transcriptional regulator. (A-C) Quantitative RT-PCR
illustrates differential expression of three genes ((A) LHX2, (B) LRRC17, (C) CDO1) in Rap1 WT
and KO ARPE-19 cells. Gene expression was normalized to GAPDH and mean expression level
for each gene as determined by the ΔCt method from 3 independent replicates is graphed in
arbitrary units. Error bars represent SDs. Significance was calculated by two-tailed unpaired TTests. *** indicates p ≤ 0.001.
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4.3

Summary of findings
Based on the genetic data presented here, human Rap1 is not required for

the protection of telomeres from NHEJ and has no obvious effect on telomere
length regulation, contrary to what was anticipated from other studies

23,78,160,213

.

The results in this chapter point to the difficulty in interpreting experiments in
which telomeric phenotypes are observed upon overexpression of shelterin
(mutant) proteins or their partial inactivation by shRNAs. The prior finding of
changes in telomere length and heterogeneity upon overexpression of Rap1
mutants 23 may have been due to nucleoplasmic titration of factors away from the
telomere that (indirectly) influence these phenotypes. Similarly, the artificial
tethering of Rap1 to telomeres may have had an effect on NHEJ that does not
reflect the normal function of the protein 160.
In addition, telomeres lacking Rap1 remained protected from DNA
damage signaling and HDR, and had a normal 3’ overhang. These findings are in
agreement with the mouse Rap1 KO, which revealed no obvious phenotype other
than that of telomeres becoming prone to undergo HDR when Ku70/80 was
absent

19

. Whether human telomeres lacking Rap1 also recombine more readily

in a Ku70/80-deficient setting is difficult to assess since deletion of human
Ku70/80 leads to rapid telomere loss and cell death 240,241.
Human Rap1 was surprisingly dispensable for telomere protection,
however its role in transcriptional regulation appears to be conserved. Due to the
low number of deregulated genes identified in vastly differing cell types, it was
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difficult to assess what transcriptional programs Rap1 participates in.
Examination of Rap1 deletion in cell lines with high metabolic activity, such as
hepatocytes, would help identify whether human Rap1 affects metabolism similar
to mouse Rap1.
These data indicate that while mammalian Rap1 has functionally diverged
away from its yeast predecessors, mouse and human Rap1 are very similar. Both
Rap1 knockout mice and human cells are viable, lack hallmarks of telomere
dysfunction, and have no overt change in telomere length settings. While the
Rap1 components of human and mouse shelterin are indistinguishable, it will be
important to query the functions of other shelterin components and associated
factors to gain a complete understanding of telomere maintenance and protection
in human cells.
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Chapter 5: Investigating the role of human POT1 at telomeres
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5.1

Introduction
As discussed in the general introduction, the deletion of mouse POT1a

and –b leads to embryonic and cellular lethality, elicits a telomeric ATR
dependent DNA damage response, increases 3’ telomere overhangs, and results
in infrequent post-replicative telomere fusions and telomere sister associations
31,32,182

.
In human cells, two isoforms of POT1 are detected by immunoblotting with

molecular weights of 71 kDa and 55 kDa

184

. The protein that migrates at 71 kDa

corresponds to full-length POT1 (POT1-FL). The isoform with the molecular
weight of 55 kDa (POT1-55) lacks the first N-terminal OB fold of POT1 and is
unable to bind telomeric DNA 34. POT1-55 is almost identical to a mutant allele of
POT1 (POT1ΔOB). POT1ΔOB cannot bind to telomeric DNA but retains its
interaction with TPP1. When overexpressed, POT1ΔOB acts as a dominantnegative

79

, presumably by binding to TPP1 and displacing endogenous POT1.

Endogenous expression levels of POT1-FL are approximately 10-fold more
abundant than POT1-55 184, and no function has been ascribed to POT1-55 as of
yet.
Partial depletion of POT1-FL with shRNAs impairs the growth of primary
but not transformed cells

184

. Furthermore, there is a modest reduction (~30%) in

the overhang signals and the precise nature of the 5’ end of the telomeres is
disrupted

184,185

. Knockdown of both POT1-FL and POT1-55 results in low levels
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of TIFs, where ~40% of cells are TIF-positive, occurring during the G1 phase of
the cell cycle 184.
In addition to protecting telomeres from the DNA damage response and
modulating the nature of the telomere terminus, POT1 has been implicated in the
cis-acting negative regulation of telomerase. Depletion of POT1 with shRNAs
or expression of the POT1ΔOB allele leads to telomere elongation

79

29

. The POT1

binding partner TPP1, on the other hand, interacts with telomerase and promotes
the recruitment of the enzyme to telomeres in vivo and enhances the processivity
of the enzyme in vitro 81.
Although the functions of POT1a and POT1b have been examined in
detail, it is as yet unclear to what extent the single human POT1-FL protein
incorporates these functions, and what role POT1-55 plays, if any. To understand
the role of human POT1 in telomere protection, we used TALENs with the aim to
generate human knockout cell lines lacking POT1. The preliminary analysis of
these human POT1-deficient cells is reported here.

5.2

Results

5.2.1 The human POT1 targeting strategy
Mouse POT1a and –b share greater than 70% amino acid identity with
human POT1

31

. Human POT1, POT1a, and POT1b, have transcripts comprised

of 19, 18 and 17 exons respectively, 15 of which are coding exons (annotated by
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Ensembl). Here, coding exons are numbered sequentially with exon 1 containing
the ATG. A strategy analogous to the mouse knockouts was employed to create
knockouts of human POT1. The mouse knockouts of POT1a and –b were
generated by deletion of exon 3, which results in an ORF with a premature stop
codon in exon 4

31

. In that study, exons 1 and 2 were not targeted because this

could bring a putative alternate start site in the 5’ UTR into frame with exon 3
coding sequences. Similar to the mouse genes, deletion of human exon 3, which
encodes aa 41 to 85, is predicted to lead to a premature stop codon in the POT1
ORF at a position four codons into exon 4. Thus, we decided to delete exon 3 in
human cells to generate a POT1-FL knockout. Neomycin, blasticidin and zeocin
donor constructs were designed with 5’ and 3’ arms homologous to the introns
surrounding exon 3 (Figure 5.1B). The anticipated resection at the TALENinduced DSB and the small size of exon 3 should allow processing to extend into
the surrounding introns such that the 5’ and 3’ arms can be used for homologydependent repair, such that the repaired allele lacks exon 3.
In silico analysis of potential exon skipping products indicated that the
ORF could be put back into frame if splicing were to occur from the exon 2 splice
donor site to exon 7, 8, 10, 12, or 14. The potential truncated products generated
by the exon skipping events would lack most of the N-terminal OB-folds that
confer the ssDNA binding activity to POT1. Therefore, some of these versions of
POT1 (splicing of exon 2 splice donor site to exon 7, 8, or 10) might still be
recruited to telomeres via their C-terminal TPP1 binding region (encoded by
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exons 10-15; see Figure 5.1A) and could potentially act as dominant-negative
mutants due to loss of their OB folds

79

. To circumvent the formation of these

truncated proteins, the donor construct was endowed with a ‘STOP cassette’
composed of an array of four copies of the SV40 poly (A) addition site

242-244

,

which should halt transcription beyond the second intron (Figure 5.1B).
Furthermore, introduction of the STOP cassette will also disrupt transcription of
the POT1-55 allele, effectively knocking out both isoforms of POT1.
Finally, given the lethality of deleting POT1a and -b in the mouse, we
considered the likely cell lethal phenotype of cells lacking both alleles human
POT1, which might be generated by TALENs (see Chapter 4). Therefore,
HT1080 fibrosarcoma cells were first infected with a retrovirus containing cDNA
encoding MYC-tagged full-length POT1 expressed from a CMV promoter (Figure
5.1B), and the retrovirus also conferred hygromycin resistance. Because the
POT1 rescuing allele is flanked with LoxP sites, exogenous POT1 can be excised
by Cre recombinase after the endogenous POT1 loci have been targeted.
Hygromycin resistant clones were isolated with the initial intent to use western
blot analysis to determine whether the exogenously expressed POT1 could be
efficiently deleted. However, the antibody used in previous studies 29 (that detects
endogenous POT1-FL and POT1-55)

184

was no longer functional. Therefore a

single clone, 20.3, was selected at random for further targeting. Eventual
identification of a commercial antibody that was able to detect POT1-FL, but not
POT1-55 (see Figure 5.1A), was used to determine that clone 20.3 expressed
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exogenous POT1-FL at similar levels to endogenous POT1-FL, and could be
effectively deleted upon treatment with Cre (Figure 5.2A-B). In addition, as shown
previously

79

, the levels of POT1 protein seem to be regulated such that

overexpression of POT1 resulted in repression of protein production from the
endogenous allele (see c20.3 in Figure 5.2B).
A TALEN pair was designed to bind a site starting in intron 2-3 and
extending into exon 3, such that the nuclease would not target the exogenous
floxed POT1 cDNA. In addition, inclusion of the intron-exon junction near the
predicted cleavage site enhances the likelihood of deleterious mutations that give
rise to either splicing errors or frame-shifts.
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Figure 5.1 TALEN-mediated inactivation of the gene for human POT1. (A) Schematic of the
human POT1 locus, and the two reported isoforms and their respective ATGs. POT1-FL, fulllength POT1 protein; POT1-55, POT1 protein lacking the first OB fold. Exons not drawn to scale,
coding exon numbers indicated (as annotated by Ensembl). Shading of exons corresponds to
protein regions they encode. Known structures of and binding sites in POT1 are indicated. Navy
line corresponds to peptide used to generate POT1 antibody used in this study (Abcam). (B) The
POT1 locus, the targeting construct, and the resulting knockout allele. F1, R1, R2-PGK, R4-Zeo:
PCR primers for genotyping. Arrows in bold: TALEN binding and cut sites. Schematic of MYCtagged hPOT1 cDNA with flanking LoxP sites (triangles), cloned into the pWZL retroviral vector
(confers hygro resistance).
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5.2.2 TALEN-mediated deletion of full-length human POT1
HT1080 clone 20.3, expressing the floxed MYC-POT1 rescuing allele, was
co-transfected with the aforementioned TALEN pair and the neomycin donor
construct (Figure 5.1B). Cells were then selected with neomycin to enrich for
POT1 alleles that had been targeted by the TALENs and repaired by HDR,
resulting in deletion of exon 3 and acquisition of neomycin resistance. PCR
analysis of neomycin resistant clones showed that 4 out of 34 (~12%) clones had
integrated the donor cassette into one allele of POT1 (Figure 5.2B). Treatment of
these heterozygous clones with Cre showed that 3 (c3, c5, c17) of the 4 clones
expressed no detectable endogenous POT1-FL protein, which migrates slightly
slower than the MYC-tagged POT1, suggesting bi-allelic disruption of the gene
(Figure 5.2B). The efficiency of Cre-mediated deletion of POT1 varied between
experiments (compare Figure 5.2A to 5.2B). Therefore, POT1-FL deletion was
verified by immunoblotting for all experiments conducted, and only experiments
that had less than 10% to undetectable levels of residual POT1 protein were
analyzed.
Sequencing of uninterrupted alleles in these heterozygous clones lacking
endogenous POT1 revealed that clones c3, c5 and c17 all contained mutations
close to the TALEN cut site (Figure 5.2C). Mutations had ablated POT1-FL by
creating a frame-shift or a defect in splicing, indicating that errors generated
during NHEJ-mediated repair of the TALEN-induced break had inactivated the
second allele of POT1. However, these NHEJ-mediated mutated alleles lacked
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integration of the STOP cassette and could still be transcriptionally active.
Therefore, while these clones served as knockouts for full length POT1, the
POT1-55 protein and potential exon skipping products generated by these
mutated alleles might still be translated. Furthermore, POT1-55 and potential
exon skipping products would not be detected by the POT1 antibody used in this
study, as it recognizes an epitope in exon 4 that is absent from the predicted
peptides (indicated in Figure 5.1A). RT-PCR with primers to exon 2 and exons 4,
9, 13 and 15 was therefore performed to determine whether POT1-55 was being
expressed. No products generated by exon skipping were detected, but products
derived from the POT1-55 isoform were visible (Figure 5.2D). Therefore POT1FL cannot be generated from the endogenous POT1 locus in clones c3, c5 and
c17, but POT1-55 is still transcribed and presumably translated in these clones.
No product was amplified in two lanes of the RT-PCR (asterisks in Figure 5.2D),
likely due to experimental error, as amplification from the cDNA was detected in
other lanes.
Telomeric ChIP on clone 17 (neo/mut) confirmed the loss of the
exogenously expressed MYC-POT1 after the retroviral introduction of Cre
recombinase, while levels of other shelterin components at telomeres were not
affected (Figure 5.3A-B). Both control and targeted HT1080 clones exhibited
slower growth when treated with Cre, presumably a consequence of Cre-induced
DNA damage

245

(Figure 5.3C). The POT1-targeted clones had a mild

proliferative defect, but did not cease proliferating. Immunoblotting of cells lacking
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endogenous POT1-FL collected at four time-points during the growth curve,
showed the reappearance of MYC-POT1 at approximately 6 days after Cre
treatment (Figure 5.3C). The reappearance of MYC-POT1 was likely due to the
outgrowth of some cells that escaped Cre infection. Retention of the exogenous
allele of MYC-POT1 presumably provided these cells a proliferative advantage
over POT1 null cells. Furthermore, MYC-POT1 was not detected at any timepoint after Cre infection in cells that had the wild type endogenous POT1 gene
(Figure 5.3D). Taken together, these data suggested that POT1-deficiency
challenged the cells. However, a puzzling aspect of the growth curve was that no
plateau or trough was observed, which would be expected if POT1-deficient cells
struggled to proliferate while POT1-proficient cells underwent enough population
doublings (at least 6 PDs, if we assume 1% cells escaped Cre) to constitute
majority of the culture. Moreover, at day 12 after ~10 PDs, MYC-POT1
expressing cells had still not completely overtaken the culture, suggesting POT1deficient cells were still proliferating. At day 20 after Cre, complete repopulation
of the culture by POT1-proficient cells was observed. Therefore, POT1-deficiency
appears to be detrimental for cells; however from the data presented here, we
cannot conclude that it is lethal.
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Figure 5.2 Loss of POT1-FL in targeted clones. (A) Immunoblotting for POT1 (Abcam
antibody) indicated that MYC-POT1 migrates more slowly than endogenous POT1, allowing us to
distinguish between exogenous and endogenous forms of POT1. Bands corresponding to MYCPOT1 and endogenous POT1 are indicated. Non-specific band serves as loading control; par,
parental HT1080 population. (B) Top, PCR of neo resistant clones with F1, R1 and R2-PGK
primers. Bottom, immunoblot of HT1080 clones with genotypes as indicated, before and 72 hours
after treatment with Cre. Blot probed with anti-hPOT1 (Abcam). (C) Top, schematic illustrating
TALEN binding sites, their predicted cutting site (grey arrows), the pyrimidine tract, splice
acceptor (SA), and the location of coding exon 3 in the POT1 locus. Bottom, relevant sequences
of the indicated clones. (D) RT-PCR on RNA from clones c5, c17 and the parental HT1080 cell
line (par). Exons amplified as indicated. Bottom, expected sizes for the two known isoforms of
POT1, and predicted sizes of potential products generated by exon skipping. Asterisks indicate
lanes where no amplification was observed.
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Figure 5.3 Deficiency of POT1-FL is not tolerated. (A) Telomeric ChIP of targeted HT1080 c17
with and without Cre treatment. Duplicate dot-blots were probed for telomeric or Alu repeats. (B)
Average percentage of telomeric DNA recovered in ChIPs with the indicated antibodies (two
independent experiments). Error bars: SEMs. (C) Growth curves of targeted and WT HT1080
clones, plotted as cumulative population doublings over time (days) after Cre treatment as
indicated. Genotypes of cell lines as indicated above. (D) hPOT1 (Abcam) immunoblot of cells in
(C) at different time-points after Cre treatment as indicated.

111

5.2.3 Telomere deprotection in POT1-deficient cells
Removal of full-length POT1 resulted in deprotected telomeres as
revealed by the induction of a strong TIF response (~65%)(Figure 5.4A-B),
similar to when mouse POT1a and –b are deleted (~75%)

31

. Depletion of POT1-

FL and POT1-55 by shRNA results in only 40% of TIFs that occur in the G1
phase of the cell cycle

184

. It is not clear whether the lower level of TIFs is due to

incomplete knockdown of POT1, or whether POT1-55 may contribute to TIF
formation in the POT1-FL knockout cells (see Chapter 6). The cell cycle
dependency of TIF formation in cells deficient for POT1-FL has not yet been
tested, however, considering 65% of cells were TIF positive, it is likely that TIFs
persist through most of the cell cycle. DNA damage signaling remained
repressed in clones 20.3 (homozygous for WT POT1) and c21 (heterozygous for
WT POT1), indicating that one allele of POT1 is sufficient to inhibit DNA damage
signaling at telomeres (Figure 5.4B), consistent with previous observations
showing that POT1a and POT1b are haplosufficient

31

. A partial, but significant

reduction of TIFs is observed when POT1 is depleted by shRNA in ATR-deficient
HCT116 cells or MEFs

148

. Treatment with an ATR inhibitor almost entirely

repressed the occurrence of TIFs in the POT1-deficient c17 clone, confirming
that human POT1-FL is required to repress activation of the ATR kinase at
telomeres (Figure 5.4B).
Metaphase spreads of cells lacking POT1-FL showed no gross
chromosomal aberrations. An increase in telomere sister associations was
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observed (Figure 5.4C-E), which also occurs upon deletion of mouse POT1a and
-b

31

. Metaphase spreads also showed several chromosome ends lacking one

(sister loss) or two (signal free ends) telomeric signals. However, this was likely
due to difficulty in detection of these telomeres by FISH, as WT cells showed the
same phenotype (Figure 5.4D). There was no significant induction of NHEJ at the
telomeres lacking POT1, as evidenced by the lack of telomere fusions (Figure
5.4E). Fragile telomeres, a readout for telomere replication problems

156

, are not

observed at telomeres lacking POT1a/b, and have not yet been assessed in this
study31. The propensity of POT1-deficient cells to undergo HDR was complicated
to test for two reasons. First, due to the short telomeres of HT1080 cells, the
telomeric fluorescent signals are weak, making the analysis of CO-FISH difficult.
Second, telomere recombination in MEFs lacking POT1a and –b is observed only
when Ku is also absent. However, since Ku-deficiency is lethal in human cells,
we were unable to co-delete Ku and POT1 240,241.
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Figure 5.4 ATR-dependent DNA damage signaling induced upon loss of full-length POT1.
(A) TIF assay on HT1080 c17 before and after deletion of POT1 with Cre. Green, telomeric FISH;
red, IF for 53BP1; blue, DNA (DAPI). (B) Quantification of TIFs assay as in (A). TIF analysis was
performed on three cell lines 36 and 72 hours after treatment with Cre. ATR inhibitor ETP-46464
254
was added to indicated cells 48 hours after Cre treatment at a final concentration of 1μM, for
24 hours. Values represent mean from three independent experiments with SDs. Calculations of
significance based on paired two-tailed Student’s T-Test (C) Metaphase spreads of c17 cell line
before and after treatment with Cre as indicated. White arrows point to examples of telomeric
‘sister associations’. (D) Aberrant features of metaphase spreads as in (C) were scored. Values
represent mean of two independent experiments, where > 400 chromosomes were scored. Error
bars: SEM. (E) Table showing occurrence of telomere fusions as detected in (C).
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5.2.4 Maintenance of telomere overhangs
Removal of both mouse POT1 proteins (or POT1b alone) results in
extended 3’ telomere overhangs

31,52,150

, whereas knockdown of human POT1-

FL, but not POT1-55, leads to a reduction in overhang signal

184,185

. Expressing

mutant alleles of POT1a or POT1b that lack their first OB fold, similar to POT155, results in increased overhang signals, presumably due to displacement of
endogenous POT1a/b by competing for binding to TPP1

246

. Interestingly, the

amount of single-stranded DNA at chromosome ends was unchanged upon loss
of POT1-FL (Figure 5.5A-B) based on detection of the single-stranded telomeric
DNA by in-gel hybridization of a labeled C-strand telomeric repeat probe to native
telomeric restriction fragments. The E. coli 3’ exonuclease, ExoI, was used to
confirm that the detected signal was derived from terminal 3’ overhangs (Figure
5.5A). Despite observing increased overhangs in the presence of DNA damage
signaling in the POT1a/b double knockout MEFs

31

, we considered the possibility

that the DDR response at human telomeres interferes with overhang processing.
However, treatment with an ATR inhibitor to repress DNA damage signaling at
deprotected telomeres in POT1-deficient cells showed no change in the telomere
overhang signals (Figure 5.5C-D).
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Figure 5.5 No change in 3’ telomere overhangs upon loss of POT1-FL. (A) Overhang
analysis of clones lacking functional endogenous POT1 loci, before and after removal of
exogenous POT1 with Cre as indicated. Left, in-gel detection of native telomeric restriction
fragments with a C-strand telomeric probe revealing the G-strand overhang signals; right, same
gel rehybridized after in situ denaturation of the DNA, revealing the total telomeric DNA in each
lane. Samples were treated with ExoI (Exonuclease I) as indicated. (B) Overhang signals from (A)
were normalized to total telomeric signals in each lane and plotted as a ratio compared to the WT
overhang signal of the corresponding cell line, labeled as ref. Values plotted for clones c5 and c3
are from one experiment. Value plotted for c17 is the mean of 3 independent experiments with
SD. Lack of statistical significance derived from two-tailed paired t-test. (C) Overhang analysis of
clones with indicated genotypes, Cre treatment and ATR treatment as described in Figure 5.4B.
Detection of native (left) and denatured (right) telomeric restriction fragments as described in (A).
(D) Quantification of overhang signals in (C) using the same methodology as in (B). Values
represent means of three independent experiments with SDs. Lack of statistical significance
derived from two-tailed paired t-test.
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Mouse POT1b recruits CST to telomeres, presumably to perform fill-in
synthesis

52

. Human POT1 interacts with CST

247,248

and may serve a similar

function of recruitment. As a positive control for alterations in overhang
maintenance, we examined the effect of a mutant of POT1 (S322L), proposed to
disrupt the POT1-CST interaction and result in extended overhangs (Hiro Takai,
unpubl.). FLAG-tagged constructs of wild type POT1 or the mutant POT1-S322L
were retrovirally expressed in clones c5 and c17 (Figure 5.6A). Overhang
analysis showed that expression of POT1-S322L in cells lacking POT1-FL indeed
resulted in an increase in overhang signal (Figure 5.6B-C), perhaps due to the
lack of CST-mediated fill-in. Although this positive control showed that the effects
of POT1 on overhang maintenance could be detected in these clones, it remains
puzzling that there is no overhang phenotype upon the deletion of POT1. POT1
might therefore be required to both stimulate resection and regulate CST
mediated fill-in to obtain the correct overhang length.
Partial knockdown of POT1-55 yields no overhang phenotype, and shRNA
targeting both POT1-FL and POT1-55 shows no additive change in overhang
signal as compared to depletion of POT1-FL alone

184

. To confirm that POT1-55

does not play a role in overhang maintenance, clone c21 (heterozygous for WT
POT1) was subjected to a second round of targeting with TALENs and the
blasticidin or zeocin donor constructs. Blasticidin and zeocin resistant clones
were screened by PCR to identify clones where both alleles of POT1 had been
targeted (Figure 5.7A). RT-PCR of homozygous targeted clones confirmed the
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lack of the POT1-55 isoform mRNA, while it was still present in clone c17, which
had a single-integration of the STOP cassette (Figure 5.7B). Similar to the earlier
observation that endogenous POT1-FL was repressed upon overexpression of
MYC-POT1 (Figure 5.3D), detection of the POT1-55 isoform by RT-PCR was
enhanced after removal of MYC-POT1 with Cre treatment (Figure 5.7B).
Therefore, regulation of POT1 protein levels might be mediated by up- or downregulation of transcription, as opposed to proteasome-mediated degradation, but
the mechanism of how this occurs is unknown. However, multiple RT-PCR
replicates need to be performed to confirm this finding of potential crosstalk
between protein levels of POT1 and transcription of its locus.
POT1-FL was also still detected by RT-PCR after Cre treatment, albeit at
much lower levels (Figure 5.7B), probably due to a low percentage of cells that
had not completely deleted the exogenous MYC-POT1 rescue allele. Quantitative
RT-PCR showed that expression of POT1-FL was significantly attenuated after
treatment with Cre (Figure 5.7C), and was confirmed by immunoblotting (Figure
5.7D). Overhang analysis of clones lacking both isoforms of POT1 showed no
change in overhang signal, indicating that POT1-55 did not contribute to
overhang maintenance.
A recurrent phenotype that was observed on these overhang gels was
mild telomere elongation after deletion of POT1-FL (Figure 5.5A, Figure 5.6B,
Figure 5.7E). Given the role of POT1 in the negative regulation of telomerase
29,79,249

, this lengthening could be due to the action of telomerase. Interestingly,
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telomere elongation was not observed after deletion of both POT1-FL and POT155 (Figure 5.7E), which would suggest that telomere extension is mediated by
POT1-55 when POT1-FL is deleted. Additional replicates need to be performed
to corroborate this observation.
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Figure 5.6 Extended overhangs in POT1-deficient cells expressing the S322L mutant.
(A) Immunoblot for FLAG and hPOT1 in clones expressing FLAG-POT1-FL (WT), FLAG-POT1S322L (S322L) or vector control. Treatment with Cre (as indicated) removes expression of MYCPOT1-FL, which all cell lines also express. n.s., non-specific band detected by the antibody
serves as a loading control. (B) Gel for overhang analysis as previously described in Figure 5.5A.
Cre treatment and ExoI treatment as indicated. Left, native gel; Right, denatured gel. wt, FLAGPOT-FL; m, FLAG-POT1-S322L; v, vector control. (C) Quantification of overhang signals in (B).
Native signals were normalized against denatured signals in the corresponding lanes and plotted
as a ratio compared to the signal in the WT sample for each cell line, labeled as ref. Values
represent means of two independent experiments, and error bars show SEMs.
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Figure 5.7 No change in 3’ telomere overhangs upon deletion of both POT1 isoforms.
(A) Genotyping PCR of zeocin (left) and blasticidin (right) resistant clones. Top, PCR with primers
F1, R1, and R2-PGK. Loss of WT allele indicates successful targeting. Bottom, PCR with primers
F1, R1 and R4-Zeo. Appearance of top band and disappearance of bottom band confirms
successful targeting. Genotypes of successfully targeted clones indicated below. (B) RT-PCR
detecting POT1-FL and POT-55. 4-fold serial dilutions of reverse transcribed cDNA were used for
PCR reactions. (C) qRT-PCR of POT1-FL in two clones before and 60 hours after expression of
Cre. (D) Immunoblot showing deletion of POT1-FL in two clones at 60 or 96 hours after Cre
expression. Genotypes as indicated. Non-specific band serves as loading control. (E) Gel for
overhang analysis of clones lacking POT1-FL or both POT1-FL and POT1-55. Genotypes and cre
treatment as indicated. Quantification of the gel shown below where overhang signals were
normalized to total telomeric signals in each lane and listed as a ratio compared to the WT
overhang signal of the corresponding cell line. WT overhang signals set to 1 are in bold with a
larger font.
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5.3

Summary of findings
Human POT1-FL, consistent with prior data

148

, is required to inhibit ATR-

dependent DNA damage signaling at telomeres. Whether POT1-55 functions as
a dominant-negative allele exacerbating the occurrence of TIFs remains to be
determined, as does the cell cycle dependence of TIF formation in POT1-FL
knockout cells. Deprotected telomeres in POT1-FL-deficient cells were not
vulnerable to NHEJ, as deduced by the lack of telomere fusions observed in
these cells. However, an induction of telomere sister associations was noted in
cells lacking POT1, but the molecular basis of these associations is not known.
Surprisingly, unlike mouse POT1a/b-deficiency

31

, human cells lacking

POT1 did not show a change in overhang status. The underlying cause of this
discrepancy is not clear, and many options remain to be tested (discussed further
in Chapter 6). Briefly, it is possible that POT1 is required to promote both
resection, and CST-mediated fill-in synthesis, thereby resulting in no overall
change in overhang signal when POT1 is deleted. Alternatively, removal of POT1
could allow telomerase to extend the overhang, and CST could be recruited to
perform fill-in synthesis independently of POT1, leaving no net change in
overhang lengths. Finally, although it seems unlikely, it is possible that steps
upstream of ATR signaling, such as RPA loading on ssDNA play a role in
overhang regulation.
The conditional knockout system we have generated in human cells will be
of great use, not only to understand the functions of human POT1, but also as a
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means to mechanistically evaluate numerous mutations recently identified in
POT1 in various cancers

250-253

(see Chapter 6). One caveat of our system is the

incomplete Cre-mediated deletion. One possible solution is to use a retroviral Cre
that confers puromycin resistance and select for Cre-expressing cells. An option
for future targeting strategies is to flank both the exogenously expressed cDNA
and the hygromycin cassette with LoxP sites, such that cells are rendered
sensitive to hyrgomycin upon treatment with Cre, and hygromycin selection can
be retained to select for other constructs of interest.
Lastly, the POT1-55 knockout cell lines described in this chapter may be
used to gain insight into the purpose of POT1-55. While the delineation of
functions that mouse POT1a and –b perform is evident, it remains unclear why
the POT1-55 isoform of human POT1 exists. It is difficult to hypothesize about
potential roles of POT1-55 in the maintenance of telomere integrity, as it
resembles a dominant negative mutant, is weakly expressed and removal of
POT1-55 displays no apparent phenotype.
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Chapter 6: Discussion
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6.1

The role of mammalian Rap1
Analysis of mouse knockouts and TALEN-mediated human knockouts of

Rap1 reveal that, unlike its yeast counterparts, mammalian Rap1 is not required
for cellular and organismal viability, does not play a major role in telomere length
regulation, and is largely dispensable for telomere protection. Loss of Rap1 does
not affect the other components of shelterin, the modification of telomeric
histones, the synthesis of TERRA, or the maintenance of the 3’ telomeric
overhang. Telomeres lacking Rap1 do not show consistent changes in their
length, do not activate the DNA damage response, or become processed by
NHEJ. However, we did find that mouse Rap1 is required to repress HDR at
telomeres redundantly with Ku70/80, a function we were unable to test in human
cells due to lethality ensuing deletion of Ku70 or -80. Remarkably, we observed
that human Rap1, like its mouse and unicellular orthologs, affects gene
expression. Therefore, we propose that the conservation of Rap1 reflects its role
in transcriptional regulation, rather than a function at telomeres.
The dispensability of Rap1 in telomere end-protection was especially
surprising with regard to previous reports implicating mammalian Rap1 as a
repressor of NHEJ

213 160

. An in vitro end-joining reaction with linear telomeric

substrates could be repressed by addition of the Rap1/TRF2 complex, but not
Rap1 or TRF2 alone

213

. Perhaps the better binding affinity of TRF2/Rap1 to

duplex telomere substrates, than that of TRF2 (Chapter 3 and

235

), allowed for

more efficient inhibition of NHEJ. An in vivo study shows Rap1 can be tethered to
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HeLa telomeres by being fused to the DNA binding domain of a S. pombe protein
that preferentially binds TTAGGG repeats (TebDB)

160

. Removal of endogenous

Rap1/TRF2 by a dominant negative mutant results in fusions, which can be
repressed by Rap1ΔCT-TebDB. Repression of NHEJ is not conferred by TebDB
itself, however, it is possible that Rap1ΔCT-TebDB acts as a neomorph. The
DNA-binding affinity of Rap1ΔCT-TebDB or its placement at telomeres may
physically occlude access of DNA repair factors. Alternatively, it is possible that
Rap1 plays a redundant role in the repression of telomere fusions in the absence
of TRF2, however our preliminary data does not support this hypothesis. In
addition, this setting of Rap1 at telomeres lacking TRF2 is highly unlikely to
naturally occur, due to the requisite binding of Rap1 to TRF2 for maintenance of
Rap1 protein levels and telomeric localization.

6.1.1 Rap1 – a conserved telomeric protein with non-telomeric functions
Several lines of evidence indicate that Rap1 is a highly conserved
component of mammalian shelterin. The human gene encoding Rap1 has
diverged little from its chimpanzee counterpart (1 base change/100 codons; 0.25
amino acid (aa) changes/100 aa), whereas the genes for other shelterin
components show much greater divergence (e.g., 3.6, 2.4, and 1.7 base
changes/100 codons and 2.2, 1.1, and 0.65 aa changes/100 aa for TRF2, TRF1,
and TIN2, respectively). Human and chimpanzee sequence was compared as
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these sequences align most closely and allow for more accurate comparison of
changes in nucleotide and amino acid sequence between shelterin proteins.
Data from the Exome Variant Server (NHLBI GO Exome Sequencing
Project, Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) [as of 02/2015])
identifies only 14 potentially deleterious (splice, nonsense, frame-shift or
missense) mutations in Rap1 in ~13,000 alleles sequenced. Compared to Rap1,
a larger number of potentially deleterious mutations have been identified in all
other shelterin components (19, 22, 50, 49 and 24 for TRF2, TRF1, TIN2, TPP1
and POT1, respectively).
Assessment of a gene damage index (GDI) derived from the 1000
Genomes Project

255

, which reports on the cumulative mutational damage in a

given human coding gene, places Rap1 in the top 20% of human genes with
regard to tolerance to mutation intolerance (Y. Itan, pers. comm.). In addition,
Rap1 ranks among the top 10% of coding human genes in terms of ‘functional
indispensability’, a characteristic that incorporates gene centrality (based on
interaction data pooled from various biological systems), structural information,
and evolutionary constraints

256

. In this regard, only TIN2 scores higher than

Rap1, as expected based on its multiple interaction interfaces in shelterin. The
aforementioned estimates of gene conservation do not necessarily highlight
essential genes, instead they aim to identify genes in which mutations may lead
to disease phenotypes. Furthermore, it is possible that Rap1 may serve an
important function in a specific tissue or cell type that we did not test, which may
explain the selective pressure placed upon Rap1.
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The level of conservation of Rap1 raises the question: what functional
aspect of Rap1 is under selective pressure? The repression of HDR is unlikely to
explain the conservation of Rap1, since the HDR phenotype only manifests itself
when Ku70/80 are absent. It is also unlikely that Rap1 has a tissue specific role
at telomeres, given that mice lacking Rap1 are alive and largely normal, and our
demonstration that Rap1 deletion from human cell lines originating from different
tissues show no overt telomere phenotype. The conservation of Rap1 is also not
explained by a role in meiosis since the Rap1 knockout mice are fertile and,
unlike yeast lacking Rap1, form a normal meiotic bouquet

19,36,217,218,257,258

. It is

not excluded that Rap1 has (as yet unknown) multiple interactions within
shelterin or with shelterin-associated factors that explain its conservation, or
alternatively, that its role at telomeres is redundant. We favor the idea that the
conservation of Rap1 is due to its role in transcriptional regulation 220-223,259 where
it may have multiple distinct interaction partners that constrain its evolution.
Given that mammalian Rap1 is unlikely to bind directly to DNA

20,193

, and

that the majority of the chromosome-internal Rap1-associated loci are devoid of
telomeric sequence

220,223

, it is expected that interacting factors recruit Rap1 to

these sites. In fact, complementation of Rap1-deficient MEFs with the Rap1
I312R allele (deficient in TRF2-binding), restores transcriptional regulation of
~85% of genes

221

, consistent with the idea that Rap1 has binding partners that

target Rap1 to these loci in a TRF2-independent manner. Identification of these
factors could potentially illuminate (as yet undefined) telomere functions of Rap1.
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Rap1 potentially evades being targeted for degradation by binding to
TRF2 (Chapter 3), which is puzzling when trying to understand how Rap1
regulates transcription independently of TRF2. One possibility is that other
binding partners are able to protect Rap1 from degradation. However, the nearly
undetectable levels of Rap1 in TRF2-depleted cells

19,22,24

, suggest that very low

amounts of Rap1 would be bound to and protected by other factors. It would
therefore be of interest to determine whether this residual non-telomeric Rap1 is
sufficient for transcriptional regulation.

6.1.2 Rationale for retention of Rap1 at telomeres
If Rap is conserved due to its role in transcriptional regulation, this begs
the question why its interaction with TRF2 and localization to telomeres is
retained. One possibility is that TRF2 is required for Rap1 to localize to some of
the chromosomal loci that it transcriptionally regulates. The aforementioned
study221 shows that ~15% of transcriptional regulation by Rap1 is dependent on
its interaction with TRF2. In addition, ~15% of loci associated with human Rap1
also contain the consensus sequence for TRF2-binding 223.
Another possibility is that telomere length influences the transcriptional
control performed by Rap1. Telomere shortening may result in displaced
Rap1/TRF2 complexes, which can then bind to additional chromosome-internal
sites. Several studies in human cells show that telomere shortening, prior to the
induction of DNA damage signaling (as detected by TIF assays), can affect
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expression of genes located both proximal

260,261

and distal

262

to telomeres. Hi-C

(chromosome capture followed by high throughput sequencing) reveals that
chromosome looping can place telomeres adjacent to genes located up to 10 Mb
away 262, which could potentially be another mode of Rap1 recruitment to loci that
it regulates. Moreover, both up- and down-regulation of transcripts are observed
following telomere shortening

262

, suggesting that gene expression does not

seem to be inhibited by proximity to heterochromatic telomeric chromatin.
Instead, it is more likely to be modulated by a transcription factor, similar to our
observations of Rap1 function in both up- and down-regulation of gene
expression.
It is unclear why telomere length should play a role in the control of gene
expression. One possibility is that telomere shortening may initiate a
transcriptional program that promotes entry into senescence. In S. cerevisiae,
when critical telomere shortening is induced by deletion of telomerase (tlc1Δ),
Rap1 relocalizes to hundreds of new target genes

263

. Redistribution of Rap1 in

yeast during the onset of senescence is dependent on Mec1 (the ATR homolog),
suggesting DNA damage also plays a role in Rap1 relocalization. DNA damage
signaling is not reported to accompany the gene expression changes observed
upon telomere shortening in human cells, which may suggest that other signals
promote senescence in mammalian cells. Alternatively, the TIF assay is not the
most sensitive method to evaluate DNA damage signaling and may miss low
frequency events that are responsible for triggering this change in cell state. It will
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be interesting to see if mammalian Rap1 is required to initiate a transcriptional
program based on changes in telomere length.

6.1.3 No Rap1 ortholog in Drosophila
Drosophila telomeres, while serving the universal function of maintaining
chromosomal integrity, lack many hallmarks of eukaryotic telomere structure and
maintenance. For instance, Drosophila species lack telomerase, maintaining their
telomeres by specialized retrotransposons instead, and they also have variable
telomere repeats and sequence at their termini (reviewed in

285

). Furthermore,

standard BLAST (Basic Local Alignment Search Tool) searches have revealed
no homologs of the shelterin components in Drosophila

286

, while most non-

telomeric human proteins have Drosophila homologs. In consideration of the nontelomeric role of Rap1, the selective pressure Rap1 appears to be under, and the
advances in annotated sequence databases, we reexamined whether Rap1
could be identified in flies. Due to the low sequence conservation of Rap1, we
used PSI-BLAST (Position-Specific Iterative), which derives a position-specific
scoring matrix that allows for detection of distant relationships between proteins.
Consistent with previous reports, PSI-BLAST of the conserved BRCT and MYB
domains of Rap1 revealed no related homologs in the Diptera order, suggesting
that other proteins may have evolved to become functional analogs of Rap1 in
flies.
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6.2

The mechanism of HDR repression at telomeres
How mouse Rap1 represses HDR at telomeres when Ku70 is absent

remains to be determined. The data in Chapter 3, showing that Rap1 when
tethered to TRF1 fails to repress HDR, while negative, would suggest a
requirement for Rap1/TRF2 complex formation in the inhibition of HDR. One
possibility is that the complex might interact with a factor that represses HDR that
Rap1 alone or TRF2 alone do not interact with. Two-hybrid and mass
spectrometry have identified numerous protein complexes bound to Rap1 and/or
TRF2

21,78,225,264-266

, but have not pinpointed a factor that could inhibit HDR.

However, these experiments were not carried out in a setting where HDR is
unleashed. Pull-down of TRF2/Rap1-associated proteins in Rap1F/FKu70-/- MEFs
(where HDR is repressed), followed by elimination of factors that remain
associated to TRF2 in a pull-down after Cre treatment (where HDR is induced),
might nominate candidates for such HDR repressing factors.
Alternatively, experiments described in Chapter 3 and aforementioned
studies

235,236

show that Rap1 can alter the DNA-binding activity of TRF2, but it is

unclear whether this is relevant to HDR inhibition (see below, section 6.2.1). In
addition, it is possible that Rap1, TRF2, and POT1a/b act together to repress
HDR (see below, section 6.2.2).
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6.2.1 The effect of Rap1 on the DNA-binding activity of TRF2
Our initial hypothesis was that Rap1 might promote binding of TRF2 to
specific telomere structures that are reminiscent of substrates for HDR, such as
the ds-ss transition at the telomere terminus. Doing so would presumably prevent
loading of HDR factors, such as BRCA2 and Rad51, which are required for
repair. Arat and Griffith

235

observed that Rap1/TRF2 binds better to a ds-ss

telomere junction than a duplex telomere template. However, we, and Januskova
et al. did not observe this difference. The conflicting results may be due to
methods of protein purification and/or use of different substrates for the gel-shift
assays.

Preliminary

gel-filtration

chromatography

revealed

various

oligomerization states within our purified proteins, which could affect their
efficiency of DNA-binding. Therefore, careful characterization of DNA binding
activities of TRF2 and Rap1/TRF2 to various telomere substrates needs to be
conducted with homogenous protein populations. Additionally, these DNAbinding studies also need to be performed in the context of the entire shelterin
complex, as POT1 binding to ssDNA may affect the binding affinity of Rap1/TRF2
to the ds-ss junction.
Insight into the mechanism of HDR repression by Rap1/TRF2 could also
be acquired by performing a displacement loop (D-loop) assay. Here, in the
presence of ATP (and Rad54 to stabilize filament formation and D-loops
Rad51

polymerizes

on

a

radiolabeled

ssDNA

probe,

which

267

),

contains

complementary sequence to one strand of unlabeled supercoiled duplex DNA.
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Strand invasion events where the ssDNA probe displaces one strand of duplex
DNA can be detected by a shift in the migration of the ssDNA probe on an
agarose gel

268

. To determine whether Rap1/TRF2 inhibits HDR by preventing

strand invasion, the d-loop assay could be modified to use telomere-repeat
sequences and compare the ability of TRF2 and Rap1/TRF2 to inhibit strand
invasion.

6.2.2 Rap1, TRF2 and POT1 may work together to repress HDR
Data shown in Chapter 3 suggests that mouse Rap1/TRF2 and POT1a or
–b may act together to inhibit HDR at telomeres. POT1a and -b were removed
from telomeres in Rap1F/FKu70-/- MEFs by treatment with an shRNA targeting
TPP1 (shTPP1). 10% of T-SCEs were observed on average when both POT1a/b
were removed by shTPP1, or when Rap1 was deleted with Cre. No additive
incidence of T-SCEs was detected when all three shelterin components (Rap1,
POT1a and POT1b) were removed, suggesting they were epistatic in their
repression of HDR. In contrast to these results, deletion of mouse TPP1, which
phenocopies POT1a/b-deficiency, did not lead to induction of T-SCEs in a Ku70deficient background (T. Kibe, unpubl.). Furthermore, deletion of TIN2, which
also largely phenocopies POT1a/b-deletion, did not lead to induction of T-SCEs
in the context of Ku70-deficiency (K. Takai, unpubl.).
One explanation to reconcile the results described above could be the
time it takes for these MEFs to become immortalized. As discussed in Chapter 3,

134

Ku70-/- MEFs rapidly downregulate HDR at telomeres through an undefined
mechanism. MEFs isolated from Ku-deficient embryos tend to have difficulty
proliferating and immortalization times can vary significantly. Therefore, it is
possible HDR was assessed too late in the TPP1/Ku70- and TIN2/Ku70-deficient
MEFs. Isolation and immortalization of Rap1F/FKu70-/- and TPP1F/FKu70-/- MEFs
in parallel would allow for a more accurate analysis of T-SCE frequencies.
Alternatively, the TPP1sh could have off-target effects leading to the appearance
of T-SCEs, which could easily be tested by treating TPP1F/FKu70-/- MEFs with the
TPP1sh and assessing induction of T-SCEs.
The lack of T-SCEs in TPP1/Ku70- and TIN2/Ku70-deficient MEFs does
not necessarily argue against the idea that POT1a/b may still act together with
Rap1/TRF2 to repress T-SCEs. As discussed previously, POT1 can interact with
TRF2

21,152,185,234

and repression of HDR by POT1 may therefore be independent

of its TIN2/TPP1-mediated recruitment to telomeres.

6.2.3 What is the telomeric substrate for HDR?
Detection of T-SCEs serve as our readout for HDR taking place at
telomeres, however this assay does not report on the source of HDR initiation.
Most of our studies have focused on the ds-ss telomere terminus as a structure
vulnerable to HDR. Another source of telomeric HDR substrates could arise from
replication errors. For instance, HDR is involved in restarting collapsed replication
forks or bypassing a lesion encountered during replication (reviewed in

135

269

). Our

preliminary analysis of MEFs lacking TRF1 (required to facilitate telomere
replication) and Ku80 showed an induction of T-SCEs, suggesting that telomeres
are also vulnerable to HDR during DNA synthesis. Therefore numerous telomere
configurations are likely to be vulnerable to HDR and further investigation into the
mechanism of HDR, especially biochemical approaches, will need to take this
into account.

6.2.4 Ku70/80-deficient cells adapt to recover repression of HDR
The downregulation of HDR at telomeres in late-passage Ku70-/- MEFs
was an intriguing finding, supporting the notion that HDR is stringently regulated
(reviewed in

270

), and warrants further investigation. First, it will be of interest to

determine whether this down-regulation of HDR is global or telomere-specific.
Assessment of global HDR using the DR-GFP assay designed in the Jasin lab
171,271

proved to be difficult due to the low rate of targeted genomic integrations in

MEFs, as well as variable transfection efficiencies and cell survival post
transfection. The DR-GFP reporter construct contains one copy of GFP that has
been rendered dysfunctional (due to the insertion of an I-SceI site), and a donor
partial GFP sequence. Induction of a DSB by transfection of the I-SceI
endonuclease, and repair by HDR using the donor GFP template restores GFP
expression. Optimal use of this assay involves integration of a single copy of the
reporter into the HPRT locus to remove confounding effects from location of and
multiple copy integration. Recent developments in genome editing using
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CRISPR-Cas9 based technologies might now allow for efficient targeting of the
DR-GFP construct into MEFs and determine global recombination levels in latepassage Ku70 deficient MEFs.
Secondly, identification of factors that perform this inhibition of HDR will be
interesting as they may illuminate aspects of HDR regulation that are as yet
unknown. A preliminary microarray to assess gene expression changes in earlyand late-passage Ku70-deficient MEFs yielded a list of 64 significantly
deregulated genes. Additional microarrays using multiple Ku70-deficient cell lines
need to be performed to see if the same hits are generated. In addition, analysis
of gene expression changes in early- and late-passage Ku-proficient cells will
assist in eliminating candidate genes that are artifacts due to long-term tissue
culture.
Lastly, the finding that Ku70-deficient MEFs down-regulate HDR in culture,
raises the question of whether other processes adapting to Ku70-deficiency
occur during embryogenesis. A notable difference between mouse and human
Ku70/80 is that acute deletion of Ku70 or Ku80 in human somatic HCT116 cells
results in lethality and massive telomere recombination

240,241,272

, while mice

lacking Ku70 or Ku80 are alive and fertile, albeit smaller and showing defects in
DNA repair

113,273

. Development of conditional mouse knockouts of Ku

components should be informative to investigate whether acute deletion of Ku
from mouse somatic cells has similar effects as those reported in human cells.
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6.3

Investigating the role(s) of human POT1
We describe the generation of conditional TALEN-mediated human

knockouts of POT1-FL and double knockouts of POT1-FL/POT1-55. Due to a
small percentage of cells that consistently escape Cre-mediated deletion of
POT1-FL, the potential cellular lethality of human POT1 knockouts cannot be
conclusively determined. Our current system provides a timeframe of 3-6 days
within which to assess telomere phenotypes of POT1-deficiency, comparable to
the approach undertaken for investigation of mouse POT1 proteins.

6.3.1 Functions of POT1 in telomere end-protection
Deletion of full-length human POT1 induces an ATR-dependent TIF
response (~65%), similar to mouse cells lacking POT1a/b (~75%)

31,148

.

Incomplete knockdown of human POT1 with shRNAs may explain the
intermediate TIF response (~40%) observed in a previous study 184. Alternatively,
it is possible that the presence of POT1-55 in cells lacking POT1-FL contributes
to the additional induction of TIFs. The rationale for this explanation is derived
from phenotypes of the dominant-negative alleles of POT1a and –b that lack their
first OB fold, akin to human POT1-55. Overexpression of POT1aΔOB or
POT1bΔOB results in a moderate induction of TIFs (~25%), presumably by
displacing endogenous POT1a/b

246

. No dominant-negative phenotype is

observed prior to deletion of POT1-FL, likely due to the 10-fold lower expression
of POT1-55 184, placing it at a disadvantage to compete with POT1-FL for binding
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to TPP1 and telomeric recruitment. Analysis of TIFs in the double knockout
POT1-FL/POT1-55 will reveal whether POT1-55 acts as a dominant-negative in
the absence of POT1-FL. It is not clear why telomeres are most vulnerable to
DNA damage signaling during G1, when POT1 is depleted by shRNAs

184

. Given

that 65% of cells lacking POT1-FL are TIF-positive, it is likely that TIFs persist
through most of the cell cycle. However, cell-cycle analysis needs to be
performed to confirm normal phase distribution.
Despite the telomere deprotection induced upon loss of POT1-FL,
telomeres do not appear to succumb to NHEJ. NHEJ is also largely repressed at
telomeres depleted for POT1 with siRNA or shRNA, which show a very low
incidence of telomere fusions (~0.1%)

184,185

. However, 2% of chromosome

fusions are detected in POT1a and –b knockout MEFs 31. Taking into account the
low frequency of chromosome fusions and the few experimental replicates
analyzed, additional assessment is required to determine whether this difference
is significant.
Deletion of human POT1-FL and mouse POT1 proteins leads to induction
of telomere sister associations, where 8% and 1.4%

31

of telomeres engage in

sister associations, respectively. The frequency of these events seem to vary
between cell lines

159

, as basal levels of telomere sister associations in the

human and mouse cell lines prior to Cre infection are 4% and 0% 31, respectively.
The telomere sister associations are not a result of NHEJ

156

. Instead, low

frequencies of telomere sister associations occur in settings where ATR is
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activated

159

, and robust induction of this phenotype is observed when telomeres

encounter replication problems

156

. Based on the low induction (2-fold) of

telomere sister associations in cells lacking POT1-FL, we do not expect to
observe a fragile telomere phenotype, but this remains to be confirmed.
Telomere sister associations are likely due to non-covalent interactions, such as
strand invasion, but the exact molecular basis of these events and their
consequences for telomere integrity remain unknown.

6.3.2 Telomere length regulation by POT1-55
An interesting observation shown in Chapter 5 is the slight increase of
telomere length in cells lacking POT1-FL, which is not detected upon loss of
POT1-FL/POT1-55. A mutant allele of human POT1 that lacks its first OB fold
(POT1ΔOB)

79

induces extreme telomere lengthening when overexpressed in

HTC75 cells, presumably through a similar mechanism as described before,
involving displacement of endogenous POT1 and loss of telomerase inhibition.
Similar to POT1ΔOB, POT1-55 may be responsible for the lengthening of
telomeres observed upon deletion of POT1-FL. However, depletion of POT1 with
siRNA also resulted in telomere elongation 29, therefore it is unclear why a setting
lacking both isoforms of human POT1 would not show telomere lengthening.
Since the experiment has only been conducted once, it is possible that
subsequent repetitions will show a telomere elongation phenotype. Additionally, if
treatment of cells lacking POT1-FL or POT1-FL/POT1-55 with a telomerase
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inhibitor abolishes the observed increase in telomere length, this would confirm
that loss of POT1 allows telomerase access to telomeres.
The raison d’être of POT1-55 remains unclear. Low levels of POT1-55
protein suggest POT1-FL will most likely outcompete it for binding to TPP1 and
residency at telomeres, although this has not been formally shown with
endogenous proteins. Furthermore, the potential dominant negative action of
POT1-55 in exposing telomeres to DNA damage signaling must be repressed.
Conversely, POT1-55 may function to facilitate telomere elongation, which could
be important in cell types that proliferate extensively, but it must also be carefully
regulated such that it does not confer immortal properties to an oncogenic
transformed cell.

6.3.3 Generation of telomeric overhangs
In stark contrast to the extended overhangs observed in POT1a/b double
knockout MEFs, and the reduction in overhangs after partial knockdown of
human POT1, no change in overhang length was observed upon deletion of
POT1-FL or POT1-FL/POT1-55. In light of the role of mouse POT1a and –b in
overhang protection

152,153

and maintenance

31,32,52,177

, and the existence of an

overhang phenotype in human POT1 knockdown studies

184,185

, it is highly

improbable that POT1-FL is not involved in telomere 3’ overhang regulation.
Instead, we favor the hypothesis that POT1 has a more complex, dual role in
overhang generation, mediating both resection and fill-in synthesis.
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The CST complex is required to generate telomeric 3’ overhangs
proposed to inhibit telomerase activity, and interacts with human POT1

51-53

, is

247,248

. It

is tempting to speculate that human POT1, similar to mouse POT1b, recruits
CST to telomeres to generate overhangs of appropriate length by fill-in synthesis.
If POT1 is required for CST recruitment to telomeres, depleting CST components
with shRNAs should have no effect on overhang length in cells lacking POT1-FL.
However, if CST associates with telomeres in the absence of POT1, depletion of
CST may result in increased overhangs, allowing us to distinguish between the
two possibilities.
Telomere 3’ overhang signal increases transiently in S/G2
extensive resection by Exo1

52

177,181

due to

. While there is no evidence that POT1 and Exo1

interact, it would be of interest to determine the changes in overhang signal after
shRNA depletion of Exo1 in POT-FL knockout cells. No change in overhang
signal would suggest Exo1 recruitment or activity is promoted by POT1. If POT1
does not play a role in facilitating Exo1 action, we would expect to see a
reduction in overhang signal. An alternate experiment to determine whether
POT1 regulates Exo1 is to assess the transient increase in overhang length in
S/G2, with the expectation of not detecting an increase if POT1 mediates Exo1
recruitment.
Based on studies in yeast

274,275

, mammalian Exo1 is presumed to be

recruited to DSBs after initial processing by the MRN complex, whereafter Exo1,
in parallel with the BLM helicase, can extensively resect DSBs
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125 124

. Therefore,

it is possible that POT1 regulates a nuclease other than Exo1, or binds to as of
yet undefined factors. However, the aforementioned experiments are likely to
yield insights into the mechanism of overhang regulation by human POT1. Our
observation of unchanged telomere overhangs upon loss of POT1 does not
replicate the 30% decrease in overhang signal detected following treatment with
an shRNA for POT1. A potential explanation of this discrepancy is that low levels
of residual POT1 may be sufficient to recruit CST, but higher levels of POT1 are
required to stimulate resection.
Other hypotheses, albeit less likely, include overhang extension by TERT,
and RPA-mediated regulation. Loss of POT1 may allow telomerase to extend 3’
overhangs, and fill-in synthesis could be mediated by CST, which can localize to
telomeres independently of POT1

51

. Steps upstream of ATR signaling may be

involved in DNA overhang regulation. For instance, similar to its role in DNA
repair, when POT1 is removed, perhaps RPA directs the 5’ to 3’ resection

276

at

the telomere terminus and recruits Polα Primase 277 to perform the fill-in reaction.

6.3.4 POT1 mutations - a compelling link between telomere dysfunction and
disease
Genomic sequencing studies in the past two years have identified 29
heterozygous POT1 mutations (and counting) in cases of Chronic Lymphocytic
Leukemia and Familial Melanoma 250-253. Majority of the mutations occur in the Nterminal regions of POT1, within the DNA-binding OB folds, and are predicted to
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act as dominant-negative alleles. There are also several C-terminal mutations
that may prove interesting to investigate, as they may illuminate as yet unknown
functions or binding partners of POT1. Additionally, the C-terminus of POT1
contains the proposed interacting domains for CST and TPP1. Analysis of Cterminal patient mutations may reveal separation-of-function mutants that are
defective in single aspects of POT1 function. Several N-terminal mutations in
POT1 have been characterized. Aside from observations of chromosomal
abnormalities, fragile telomeres, and telomere lengthening, exact mechanisms of
pathogenesis remain to be elucidated. The TALEN-mediated conditional
knockouts of human POT1 will provide a useful resource to identify the
dysfunctional phenotypes encoded by these mutations.
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Chapter 7: Materials and Methods
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7.1

General procedures

7.1.1 Mammalian cell culture
MEFs were isolated from E13.5 embryos and maintained in DMEM
supplemented with 1 mM sodium-pyruvate, 100 U/mL penicillin, 0.1 µg of
streptomycin per ml, 0.2 mM L-glutamine, 0.1 mM nonessential amino acids, and
15% fetal bovine serum (FBS). Primary MEFs were immortalized by retroviral
infection with pBabeSV40-LT (gift from Greg Hannon).
HCT116, HT1080, ARPE-19, and HeLa1.3 cells were grown in Dulbecco
modified Eagle medium (DMEM) supplemented with L-glutamine, penicillinstreptomycin, nonessential amino acids and 15% bovine calf serum (BCS,
HyClone). SV40-large T transformed (neo resistant) BJ fibroblasts were cultured
in complete DMEM containing 199 medium (4:1) and 10% BCS.

7.1.2 Retroviral gene delivery
For infection of mouse cells, 24 h prior to transfection, 5x106 Phoenix
ecotropic packaging cells were plated in 10 cm dishes. Phoenix cells were
transfected with 20 μg of the appropriate plasmid by calcium phosphate
precipitation. Media was changed 6-8 h after transfection. 36 h after transfection,
media containing virus was collected, and filtered through 0.45 μM filter.
Polybrene was added to a final concentration of 4 μg/mL. MEFs that had been
plated 12-24 h earlier in 10 cm dishes and were ~40% confluent were infected. 3

146

infections were performed at 12 h intervals. Time zero was set at 12h after first
infection. Infected cells were then selected for with the appropriate antibiotic
(puromycin 2μg/mL, hygromycin 90μg/mL). Selection was deemed complete
when uninfected control cells all died in the presence of antibiotic.
For human cells, the above protocol was used with the following
modifications. Phoenix amphotropic packaging cells were used to produce virus.
Human cells were infected 3 times at 4 h intervals. Time zero was set at 12 h
after first infection. Puromycin was used at 750 ng/mL, hygormycin was used at
135 μg/mL.
For infection with Cre recombinase, a Sloan Kettering facility produced
virus from retroviruses pMMP Hit&Run Cre and pWZL Cre. The viruses were
used to infect cells as described above. Selection with hygromycin followed
infection with pWZL Cre. No selection was performed after treatment with
Hit&Run Cre.
For the tamoxifen-inducible Cre-ERT2 system, 500nM of 4-OHT was
added to cells. Media was changed 6 h later and that was deemed time zero.

7.1.3 Growth curves
Growth curves were presented as population doublings over time and
were calculated by the following formula: original PD + (ln(# cells counted/# cells
seeded)/ln(2)).

147

7.1.4 Immunoblotting (IB)
Immunoblotting was performed as previously described

22

. Briefly, cells

were harvested by trypsinization, resuspended in Laemmli buffer (100mM TrisHCl pH 6.8, 200 mM DTT, 3% SDS, 20% glycerol, 0.05% bromophenol blue) at
10,000 cells per µl, denatured for 5 min at 95°C, sheared with an insulin needle,
and resolved on SDS/PAGE gels using 100,000 cells per lane. Blots were
blocked in 5% non-fat dry milk/PBS + 0.1% Tween20.

7.1.5 Coimmunoprecipitation (Co-IP) from transfected 293T cells
2 x 106 293T cells were plated 24 h before co-transfection with calcium
phosphate co-precipitation using 10 µg each of FLAG-tagged and MYC-tagged
constructs. Cells were harvested at 36 h after transfection, washed once with
PBS, and lysed on ice for 10 min in a high salt buffer (50 mM Tris-HCl pH 7.2,
400 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, 1 mM DTT, 1 mM
PMSF and cocktail of protease inhibitors). Salt concentration was brought down
to 200 mM by addition of ice-cold water (drop-wise while mixing) and lysates
were spun at 4°C at 14,000 rpm for 10 min. Supernatants were used in
immunoprecipitations. 5% of the supernatant was saved as ‘input’ for western
blot analysis and the remaining supernatant was pre-cleared with preblocked
(10% BSA in PBS overnight) protein G-Sepharose beads for 1 h at 4°C. Lysates
were incubated overnight at 4°C with a 40 µl slurry of Sepharose beads
conjugated to 9E10-Myc or M2-FLAG mouse monoclonal antibody. Beads were
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washed 5 times with ice-cold PBS. Proteins were eluted by boiling for 5 min in
Laemmli buffer and analyzed by SDS-PAGE and immunoblotting.

7.1.6 Immunofluorescence-fluorescence in situ hybridization (IF-FISH)
IF-FISH was conducted as previously described 278. Briefly, cells grown on
coverslips were fixed for 10 min in 2% paraformaldehyde/3% sucrose at room
temperature, followed by three 5 min PBS washes. Coverslips were incubated in
blocking solution (1 mg/ml BSA, 3% goat serum, 0.1% TritonX-100, 1 mM EDTA
in PBS) for 30 min, followed by incubation with primary antibodies diluted in
blocking solution for 1 h at rt. Cells were washed three times for 5 min with PBS
and then incubated with secondary antibodies diluted in blocking solution for 30
min at rt. Antibodies used were as listed at the end of this chapter. Coverslips
were dehydrated with 70%, 95% and 100% ethanol and allowed to dry.
Hybridizing solution (70% formamide, 0.5% blocking reagent from Roche, 10 mM
Tris-HCl pH 7.2 and FITC-OO-(CCCTAA)3 or TAMRA-OO-[TTAGGG]3 PNA
probe from Applied Biosystems) was added to each coverslip and denatured at
80ºC for 5 min, followed by a 2 h incubation at rt. Two 15-min washes in 70%
formamide/10 mM Tris-HCl pH 7.2 and three 5-min washes with PBS were
performed. DNA was stained with DAPI in the PBS washes and coverslips were
mounted using antifade reagent ProLong Gold from Life Technologies. Images
were captured using a Zeiss AxioPlan II microscope with a Hamamatsu C4742-
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95 camera using Volocity software from Perkin Elmer. For distance of telomeres
from nuclear membrane, calculations were made using Image J software.

7.1.7 Telomeric FISH and chromosome orientation-FISH (CO-FISH)
Telomeric FISH and CO-FISH were conducted as previously described
119,154

. Briefly, colcemid was added to cells 2 hours prior to harvest. Cells were

collected by trypsinization, swollen in 0.075 M KCl and fixed overnight at 4ºC in
methanol:acetic acid (3:1). Metaphase spreads were dropped on glass slides and
aged overnight. Slides were hybridized with FITC-OO-[CCCTAA]3 or TAMRAOO-[TTAGGG]3 PNA probe in hybridizing solution, denatured at 80ºC for 5 min
and incubated for 2 h at rt. Two 15-min washes in 70% formamide/10 mM TrisHCl pH 7.2 and three 5 min washes with 0.1 M Tris-HCl pH 7.2/0.15 M
NaCl/0.08% Tween20 were performed. DAPI was added to last wash for DNA
stain. Slides were dehydrated in 70%, 95%, and 100% ethanol and mounted
using ProLong Gold antifade from Life Technologies. Images were captured
using a Zeiss AxioPlan II microscope with a Hamamatsu C4742-95 camera using
Volocity software from Perkin Elmer. For CO-FISH, BrdU:BrdC (3:1) was added
14 h prior to harvest. Harvesting and metaphase conditions were as described for
FISH. Slides were treated with 0.5 mg/ml RNase A diluted in PBS, stained with
0.5 µg/ml Hoechst 33258, exposed to 5400J/m2 of UV light and subsequently
digested with 800 U of Exonuclease III from Promega for 10 min at room
temperature. Slides were rinsed with PBS, dehydrated with 70%, 95% and 100%
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ethanol and sequentially hybridized with TAMRA-OO-[TTAGGG]3 and FITC-OO[CCCTAA]3 for 2 h each at rt, without denaturation. Washing, mounting and
capture conditions were as described for FISH.

7.1.8 Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described

79

. Briefly, cells were fixed

1% paraformaldehyde/culture medium for 45 min at room temperature. Glycine
was added to 0.2 M to stop the cross-linking. Cells were pelleted by
centrifugation and washed with ice-cold PBS, followed by a final wash in PBS/1
mM PMSF. The cells were resuspended in cell lysis buffer (5 mM PIPES (pH
8.0), 85 mM KCl, 0.5% Nonidet P-40, 1 mM PMSF, protease inhibitor cocktail
from Roche), incubated on ice for 15 min and sonicated for 10 min (30 sec on/30
sec off) in a water-bath sonicator. Supernatants of lysates were incubated with
the appropriate antibody at 4 °C overnight and then for 45 min with ChIP-grade
protein G magnetic beads (Dynal, Invitrogen). Immunoprecipitated DNA was
washed, eluted from the beads, and precipitated with ethanol after reversal of the
cross-links and Proteinase K treatment. The DNA samples were dissolved in
water, boiled and loaded on dot blots, and hybridized with an 800-bp probe
labeled with Klenow and a primer for the C-rich telomeric repeat strand. Signal
intensity measured by ImageQuant software was normalized to the signals of the
input DNA on the same blot.
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7.1.9 Genomic blotting, telomere length and telomere overhang analysis
Cells were harvested by trypsinization, washed with PBS, and either
pelleted and frozen at -80ºC (for telomere length analysis) or processed
immediately (for genotyping and telomere overhang analysis) for genomic DNA
collection. Genomic DNA was extracted as previously described 4. DNA for
genotyping was digested with appropriate enzymes, quantitated by fluorometry
using Hoechst 33258 and 10 µg was loaded on a 0.7% agarose gel run in 0.5X
TBE. DNA for telomere overhang and length analysis was digested with MboI
and AluI, quantified using Hoechst, and 1 µg was run on 0.7% agarose gels in
0.5X TBE.
For genomic blots used for genotyping and telomere length analysis, the
gels were depurinated with 0.5N HCl, denatured and neutralized using standard
Southern blotting procedures and transferred as previously described 4. For
genotyping, probes (indicated in figures) were Klenow-labeled using random
primers and α-32P-dCTP. For telomere length analysis, a Sty11 probe with ~800
bp of telomeric repeats

279

was Klenow-labeled with the TelC [CCCTAA]4 oligo

and α-32P-dCTP. Membranes were exposed to PhosphorImager screens and
quantified with ImageQuant software.
For telomere overhang analysis, gels were dried and probed with a
[CCCTAA]4 end-labeled with Polynucleotide kinase and γ-32P-ATP as previously
described

280

. The gel was washed at 55°C three times for 30 min each in

4xSSC, once for 30 min in 4x SSC/0.1% SDS, and exposed to a PhosphoImager
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screen overnight. After the image was captured, the gel was denatured in 0.5 M
NaOH, 1.5 M NaCl for 30 min, neutralized with two 15 min washes in 0.5 M TrisHCl pH 7.5, 3 M NaCl, and hybridized overnight with the same probe at 55°C.
The gel was washed and exposed as above. The ss G-rich overhang signal in
the native gel was quantified with ImageQuant software and normalized to the
total telomeric DNA quantified after the gel had been denatured and rehybridized
with the telomeric probe.
For telomere overhang analysis of mouse genomic DNA, 1x106 cells were
resuspended in PBS and mixed 1:1 (v/v) with 2% agarose (SeaKem) in PBS and
set in plug molds (BioRad). Plugs were digested overnight with Proteinase K
buffer (10mM Tris-HCl pH 8.0, 250mM EDTA, 0.2% sodium deoxycholate, 1%
sodium lauryl sarcosine), washed four times for 1 hr each with TE, with 1 mM
PMSF in the last wash. Plugs were washed once more with H2O and digestion
buffer. Plugs were incubated overnight at 37°C with 60 U MboI. The following
day, the plugs were washed once in TE, and once in 0.5xTBE, and loaded onto a
1% agarose/0.5xTBE gel. Samples were run for 24 hours on a CHEF-DRII PFGE
apparatus (BioRad) in 0.5xTBE. The settings were as follows: initial pulse, 5 s;
final pulse, 5 s; 6 V/cm; 14°C. Gels were dried and the same protocol outlined
above was followed for hybridization, detection of signal, and quantification.
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7.1.10 Northern analysis for TERRA
Total RNA was prepared using RNeasy Mini Spin columns (QIAGEN)
according to the manufacturer’s instructions and northern blot analysis was
performed as previously described

281

. Briefly, 20µg of RNA was loaded onto

1.2% formaldehyde agarose gels and separated by gel electrophoresis. RNA was
transferred to a Hybond-N+ membrane and crosslinked in a UV Stratalinker. The
blot was prehybridized in Church mix at 55°C for 1 hour, followed by overnight
hybridization with a Sty11 probe

279

. The blot was washed 3 times for 15 minutes

at 55°C with Church wash and then exposed to a Phosphorimager screen for 5
days. Screens were scanned using ImageQuant software and quantified in Image
J using the ethidium bromide stained 18S RNA as a loading control for
normalization.

7.1.11 Microarray analysis
Total RNA was isolated from cell lines using RNeasy Mini spin columns
(QIAGEN) with DNase digestion, according to the manufacturer’s instructions.
Microarray hybridization and scanning were performed at the Genomics core
facility at Rockefeller University, using Whole Human Genome DNA microarrays
(Illumina HumanHT-12 v4). The data was analyzed using GeneSpring v12.6.
Normalization was performed using quantiles and data was filtered to remove
absent genes using flag calls.
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Experiments for HT1080 and HCT116 cell lines were performed in
replicate, using two independent isolations of RNA. Differentially expressed
genes were identified after performing moderated T-Tests and applying the
Benjamini-Hochberg False Discovery Rate method. A further fold change of 3 or
2.75 was applied to the HT1080 and HCT116 clones respectively to identify
genes that were highly transcriptionally deregulated due to the absence of Rap1.
Microarrays for ARPE-19 were not performed in replicate and therefore an
extremely stringent fold change threshold was applied to remove false negatives
and identify differentially expressed genes, which were subsequently validated by
qRT-PCR.

7.1.12 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
For qRT-PCR, cDNA was prepared from 1µg of total RNA by using
Thermoscript Reverse Transcriptase (Invitrogen). Quantitative PCR reactions
were performed using Life Technologies SYBR Green Master Mix on an Applied
Biosystems 7900HT Sequence Detection System. Differences between samples
calculated using QuantStudio software (Applied Biosystems) using the ΔCT
method and were normalized to GAPDH.
For human Rap1, two independent isolations of RNA and reverse
transcriptase reactions were conducted and the experiment was repeated six
times for clones 23, 25, 30 and the parental cell line. The experiment for clone 26
was conducted in triplicate. For human POT1, qRT-PCR was conducted in
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triplicate. Data was pooled to derive the mean averages and standard deviations.
Significance was calculated using a two-tailed unpaired T-Test. Primers used are
listed at the end of this chapter.

7.1.13 Nickel-affinity purification of His-tagged proteins
Human shelterin proteins were produced in baculovirus prior to this work20.
Sf9 insect cells were infected with baculovirus expressing shelterin components
for two days and purified as previously described

22

. Briefly, infected cells were

harvested and lysed in 5 ml of cold lysis buffer (50 mM Tris, pH 7.4, 150 mM
NaCl, 1% Triton X-100, 5 mM β-mercaptoethanol supplemented with Roche
Applied Science protease inhibitor mixture) per 100 ml of cell culture. All
subsequent steps were done at 4 °C. After incubation on ice for 10 min, the
mixture was sonicated and cleared by centrifugation at 13,200 rpm for 20 min.
His tagged proteins were isolated using chelating Sepharose fast flow (GE
Healthcare) nickel resin. Proteins were bound to the resin, washed and eluted
with 1 M Imidazole. Protein yield and purity was quantified on SDS-PAGE gels
against a BSA standard.

7.1.14 Electrophoretic Mobility Shift Assays (EMSA)
Binding reactions were conducted as previously described

20

. Briefly, of

EMSAs were conducted in in 4% Glycerol, 0.5 μgE. Coli DNA, 20 mM GlycineKOH [pH 9.0], 10 mM DTT, and 50 ng β-casein per 20 μl. Reaction with probe
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and protein were incubated at 4°C for 30 min and run on a 0.6% agarose gel in
0.1 × TBE at 4 ° C. Gels were dried onto DE81 paper and analyzed by
autoradiography or by exposure on a Phosphorimager. DNA probes were
prepared as described previously

11

. In brief, the HindIII/Asp718 fragment

containing (TTAGGG) repeats was purified from pTH12
12

32

11

and filled in with [α-

P]dCTP and Klenow enzyme. Other probes used in this study were generated

by annealing oligos (sequence is section 7.2), digesting with Asp718 and filling in
with [α- P]dCTP and Klenow. Dissociation constants were calculated using
32

SigmaPlot by graphing % of bound probe against protein concentration.

7.1.15 Genotyping and sequencing
PCR was performed in 25 µl containing 50 ng of DNA, 0.2 µM of each
primer, 0.1 µM dNTPs, 1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl pH 8.0, and
0.5 U of TaKaRa Taq polymerase. Conditions were as follows: 95°C for 4 min, 25
cycles of 95°C for 30 sec, 60°C for 30 sec, 72°C for 45 sec and final extension at
72°C for 5 min.
Sequencing of heterozygous clones to identify mutations was conducted
by PCR-amplifying the remaining ‘WT’ allele. PCR products were eluted from
agarose gels and sequenced. For sequencing of homozygous ‘WT’ clones,
eluted PCR products were cloned by TA cloning (Life Technologies). A minimum
of 8 resulting TA clones per cell line were sequenced to identify mutations in both
alleles.
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7.1.16 Gene targeting and cell cloning
All cell lines were transfected in 10 cm dishes at a density of 3x106 cells
using Lipofectamine 2000 (Life Technologies) with 4 µg of each TALEN construct
and 20 µg of the appropriate donor construct. 48 hours after transfection, all cell
lines, except for HeLa1.3, were plated in selection medium in 10 cm plates at
varying densities ranging from 3,900 to 500,000 cells (using two-fold dilutions).
HeLa1.3 cells were plated in 10 cm dishes using two-fold dilutions starting from
8000 cells down to 75 cells. G418 was used at 1 mg/ml to select neomycinresistant HCT116 cells, at 900 µg/ml for HT1080 cells, and at 800 µg/ml for
ARPE-19 cells. Blasticidin was used at 5 µg/ml for HT1080 and HeLa1.3
selection, and at 2.5 µg/ml for SV40LT BJ selection. Zeocin was used at
100µg/ml for HT1080 cells.
For Rap1 targeting, clones emerged at a frequency of approximately 1
clone per 500 plated HCT116 cells, 1 clone per 2,600 plated HT1080 cells, 1
clone per 7,800 plated ARPE-19 cells, 1 clone per 125 plated HeLa1.3 cells, and
1 clone per 62,500 plated SV40LT BJ cells. The media was not changed after
initial plating.
For POT1 targeting, clones emerged at a frequency of approximately 1
clone per 3000 plated HT1080 cells in neomycin selection, 1 clone per 4000
plated HT1080 cells in zeocin selection, and 1 clone per 15 plated HT1080 cells
in blasticidin selection. 75% of HT1080 clones picked after blasticidin selection
died after continuous culturing in blasticidin.
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Clones were picked 12 days later for all cell lines except the SV40LT BJ
clones, which were picked 3 weeks after plating. Approximately 60-70 clones
were picked for each cell line using cloning cylinders from plates that contained
well-spaced clones and the cells were transferred into 24 well plates. After
reaching confluence, half of the cells in each well were harvested to extract
genomic DNA, while the remaining cells were expanded into 6 well plates.
Approximately 30-40 clones were screened per cell line.

7.2

Mouse and human TERF2IP targeting

7.2.1 Mouse TERF2IP targeting (by Agnel Sfeir)
The Rap1 targeting vector was generated by cloning restriction fragments
from a BAC clone into the pSL301 vector (Invitrogen). A neomycin cassette
flanked by 2 FRT sites and containing a LoxP site was inserted into a CspCI site
in the first intron. A second LoxP site, together with an NdeI site was introduced
by inserting an oligonucleotide into a BsmBI site within the second intron. The
vector was linearized with NotI and gene targeting of C57BL/6J ES cells was
performed using standard techniques. ES cell clones with the correct integration
were identified by southern blots of NdeI digested DNA using a 350-bp probe
downstream of exon 3 outside the targeting vector. A correctly targeted ES clone
was injected into C57BL/6J blastocyst to generate chimeric male founders.
Crossing the chimeras to albino C57BL/6J females delivered offspring with the
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Rap1F/+ genotype. Rap1 targeted mice were maintained in a C57BL/6J
background. The neomycin cassette was deleted by crossing the mice to the
FLPe-deleter mouse strain (Jackson Labs). The Rap1 ex2 allele was generated by
Δ

crossing the Rap1F/+ to the E2a-Cre deleter strain (Jackson Labs). Rap1F/F mice
were crossed with Ku70-/+ mice (obtained from F. Alt, Harvard Medical School,
Boston MA).

7.2.2 TALENs and the TERF2IP targeting construct
The heterodimeric TALEN pair for TERF2IP targeting was constructed
using the following RVD sequences. LEFT2: 5’-HD-NG-NN-NG-NN-HD-NG-NNNG-NG-HD-NG-NG-HD-NG-HD-NG, RIGHT1: 5’-HD-NG-NN-NN-NI-NN-NG-NGHD-NG-HD-NG-NG-NI-NG-NG-3’.

TALENs

were

constructed

by

Dirk

Hockemeyer. The PGK Neomycin cassette from the PL451 vector (NCI) was
liberated using restriction enzymes NheI (5’) and BstBI (3’) and ligated into NheIand BstBI- digested pSL301 (cloning vector from Invitrogen). The pEF Blasticidin
cassette from plasmid pEF/Bsd (Life Technologies) was released using NheI (5’)
and EcoRI (3’) and ligated into NheI- and EcoRI- digested pSL301. The 5’ and 3’
homology arms were PCR-amplified with restriction site overhangs from genomic
SV40LT BJ fibroblast DNA. Primers for PCR of the 5’ arm were as follows: 5’ATGCGGTACCTTGCCCAAACTCCTGTCTTCTTAGGGC-3’

and

GCATGCTAGCAGAGAAGAACAGCACAGATTAGCAATAGCC-3’.
PCR

of

the

3’
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arm

Primers

were

5’for
5’-

ATGCTTCGAACTAGATTTACTCATTATTTTTTTCCCTACC-3’

and

5’-

GCATTTCGAACCTGTAATCCCAGCACTTTGGGAG-3’. The resulting 600 bp 5’
homology arm ends 7 bp from the intron 1/exon 2 junction and has KpnI and
NheI sites on the 5’ and 3’ ends, respectively. The resulting 578 bp 3’ homology
arm starts 32 bp from the exon 2/intron 2 junction and has BstBI restriction sites
at both ends. The homology arms were cloned into the relevant restriction sites in
pSL301 containing either the PGK Neomycin or pEF Blasticidin. The 3’ homology
arm insertion was screened for orientation and the donor constructs were
sequenced

using

the

GCTCGCGTCGTGCAGGACGT-3’

following
(PGK

primers:
internal

T7,
primer),

T3,

5’-

and

5’-

GCTGTGCTCGACGTTGTCAC-3’ (Neomycin internal primer).

7.3

POT1 gene targeting

7.3.1 TALENs and the POT1 targeting construct
The heterodimeric TALEN pair for POT1 targeting was constructed using
the following RVD sequences. LEFT: 5’-NI-NI-NI-NI-NG-NI-NG-NG-NN-NI-NI-NINN-NG-HD-NI-NN-3’, RIGHT: 5’-NN-NI-NN-HD-NI-NI-NG-NI-NI-NG-HD-NG-NNNN-NI-3’. TALENs were constructed by Siobhan Gregg, Supawat Thongtip and
Shaheen Kabir using the FLASH assembly system (REYON REF). The PGK
Neomycin cassette from the PL451 vector (NCI) was liberated using restriction
enzymes NheI (5’) and BamHI (3’) and ligated into NheI- and BamHI- digested
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pSL301 (cloning vector from Invitrogen). The SV40 Zeocin cassette from
pSV40/Zeo2 (Invitrogen) was liberated using restriction enzymes NheI (5’) and
BamHI (3’) and ligated into NheI- and BamHI- digested pSL301. The pEF
Blasticidin cassette from plasmid pEF/Bsd (Life Technologies) was released
using NheI (5’) and BamHI (3’) was liberated using restriction enzymes NheI (5’)
and BamHI (3’) and ligated into NheI- and BamHI- digested pSL301. The pEF
promoter of the blasticidin cassette was replaced with a PGK promoter by cloning
it out of PL451 by NheI/XbaI digest and cloning it into NheI-digested pEF
blasticidin. The STOP cassette was digested out of Lox-Stop-Lox TOPO
(available from Addgene, Tyler Jacks lab) with BamHI and EcoRI and cloned into
the relevant sites of the neomycin, blasticidin and zeocin donor constructs. The 5’
and 3’ homology arms were PCR-amplified with restriction site overhangs from
genomic HT1080 DNA. Primers for PCR of the 5’ arm were as follows: 5’CTACCACCAGTGTTTGAAGTTATCG-3’

and

5’-

AATATTTTACCTGACTTTCAATATTTTAAAGC-3’. Primers for PCR of the 3’ arm
were

5’-

CTCTGTATTGTTCACTGAAACTAGTTAGCAC-3’

and

5’-

CCAGAAGTGCATTGAACAAAAAAGCTC-3’. The resulting 647 bp 5’ homology
arm ends 14 bp from the intron 2/exon 3 junction and has XhoI and NheI sites on
the 5’ and 3’ ends, respectively. The resulting 649 bp 3’ homology arm starts 43
bp from the exon 3/intron 3 junction and has EcoRI restriction 5’ and a blunt 3’
end. The homology arms were cloned into the relevant restriction sites in pSL301
containing either the PGK Neomycin or pGK Blasticidin or pSV40 Zeocin.
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7.4

List of primers

7.4.1 Genotyping

Mouse Rap1 primers:
F1: 5’-CATGCACTTGTACACATACAA-3’;
F2: 5’-GCTTCTTCCACCAAAACTGC-3’;
R: 5’-TTTGACAGTTGATAGGAAATGAAC-3’

Human Rap1 primers:
F1: 5’- GTGGATTGTGGTACGT GGCCCAGATCTGCC-3’;
R1: 5’-TAACATACCACAACCTCCTCAAACTCCCGG-3’;

POT1 primers:
F1: 5’-GTGTACTTCAGAACCATGTATAGCACACC-3’
R1: 5’-GGGCTTCATAGTTTCCACTAAAGAGCAGGC-3’

PGK internal primer:
R2: 5’-CATCTGCACGAGACTAGTGAGACGTGCTAC-3’
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Zeocin internal primer:
R4: 5’-GAGCACCGGAACGGCACTGGTCAACT-3’
7.4.2 RT-PCR

Human GAPDH (published in 282)
5’-TGCACCACCAACTGCTTAGC-3’
5’-GGCATGGACTGTGGTCATGAG-3’

Human CDO1
5’-CGCCAAGTTCGACCAGTACAGG-3’
5’-GGTATGATCATGAATACTGCTGCC-3’

Human LHX2
5’-GGACGGTAGCATCTACTGCAAGG-3’
5’-CCAAGTCCCGAGCGCGCATCACC-3’

Human LRRC17
5’-CAAGCCTGAGGTGGACTCAACT-3’
5’-CTGGAGGGATGTTGTTTGGCAC-3’
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POT1 coding exon 2 (anneals to both isoforms)
5’-CACCCCTGAATCAACTTAAGGGTGG-3’

POT1 coding exon 3 (anneals only to POT1-FL)
5’-CTGGTCCACAATAGTTACAACTGAGC-3’

POT1 coding exon 2-4 junction (anneals only to POT1-55)
5’-TATACTTGAATCAGTTCCTTTGC-3’

POT1 coding exon 4 (anneals to both isoforms)
5’-GCTCCGTCCACTTCTGCTTTGCCCA-3’

POT1 coding exon 9 (anneals to both isoforms)
5’-CAGACTGAAATAGTCTTCTGGGC-3’

POT1 coding exon 13 (anneals to both isoforms)
5’-CCATGAGATAGGCTTCTAGTACTCC-3’

POT1 coding exon 15 (anneals to both isoforms)
5’-CATCTTCTGCAACTGTGGTGTC-3’
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7.4.3 EMSA probes

Junction probe
5’-ATGCGGTACCGGATGTCACTCAGCAGACGGTTAGGGTTAGGGTTAGGG
CACTAGTTAGGGTTAG-3’
5’-CTAGTGCCCTAACCCTAACCCTAACCGTCTGCTGAGTGACATCCGGTACC
GCAT-3’

[TTAGGG]3-repeat probe
5’-ATGCGGTACCGGATGTCACTCAGCAGACGGTTAGGGTTAGGGTTAG-3’
5’-CTAACCCTAACCCTAACCGTCTGCTGAGTGACATCCGGTACCGCAT-3’

7.5

List of shRNAs

Mouse TPP1:
Target sequence 5’-GGACACATGGGCTGACGGA-3’

Mouse Rap1:
sh1 target sequence 5’- ACAGGCAATGCCTTGTGGAAA -3’
sh2 target sequence 5’-CTTCATCTCCA CGCAGTACAT-3’
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7.6

List of antibodies
ID

Source

Uses

hRap1

765

de Lange lab

ChIP, IB

hTRF2

647

de Lange lab

ChIP

hTRF1

371

de Lange lab

ChIP

hTIN2

864

de Lange lab

ChIP

ab124784

Abcam

IB, ChIP

hTPP1

1151

de Lange lab

ChIP

mRap1

1252

de Lange lab

IB, IF, ChIP

mTRF2

1254

de Lange lab

IB, ChIP

mTRF1

1449

de Lange lab

IB, ChIP

mTIN2

1447

de Lange lab

IF, ChIP

POT1a

1221

de Lange lab

IB, ChIP

POT1b

1223

de Lange lab

IB, ChIP

MYC

9E10

Calbiochem

IB, IP

MYC

9B11

Cell signaling

IF, ChIP

FLAG

M2

Sigma

IB, IP, IF

53BP1

100-304

Novus

IF

Antigen

POT1
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Lamin A

L1293

Sigma

IF

Alpha-tubulin

T9026

Sigma

IB

Chk2

611570

BD Transduction

IB

Chk1-P

Ser345

Cell Signaling

IB

Chk1

Sc-8408

Santa Cruz

IB

ab9045

Abcam

ChIP

ab1220

Abcam

ChIP

ab8898

Abcam

ChIP

ab77256

Abcam

ChIP

ab10478

Abcam

ChIP

ab10480

Abcam

ChIP

06-598

Millipore

ChIP

H3K9me1
H3K9me2
H3K9me3
HP1alpha
HP1beta
HP1gamma
Acetyl Histone H4
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7.7

List of cell lines
Organism, Organ

Notes

TRF2F/- p53-/-

Mouse, E13.5 MEFs

24

TRF2F/F Ku70-/-

Mouse, E13.5 MEFs
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Rap1F/F

Mouse, E13.5 MEFs

This work

Rap1Δex2/ Δex2

Mouse, E13.5 MEFs

This work, Agnel Sfeir

Rap1F/F Ku70-/-

Mouse, E13.5 MEFs

This work

Rap1F/F Ku70+/-

Mouse, E13.5 MEFs

This work

Rap1F/Δex2 Ku70-/-

Mouse, E13.5 MEFs

This work

TRF1F/F Cre-ERT2

Mouse, E13.5 MEFs

Agnel Sfeir

HT1080

Human, Fibrosarcoma

ATCC

HCT116

Human, Colorectal

ATCC

Cell Line

carcinoma
ARPE-19

Human, Retinal pigment

ATCC

epithelial
BJ

Human, foreskin

ATCC

Human, Cervical

22

HeLa1.3

adeoncarcinoma
Phoenix ecotropic

Human, Epithelial

Phoenix amphotropic

Human, Epithelial

293T

Human, Kidney
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